Director of Business Development
Meelis Kadaja is a Director of Business
Development at Icosagen. He is responsible for company’s business strategy, commercialization of technologies, therapeutic, diagnostic, research antibodies, and communication with partners. He has studied previously the replication
of small DNA viruses, and the maintenance of adult tissue specific stem cells. He received his Ph.D and MBA in Tartu University, Estonia, and he completed his postdoctoral training in the Rockefeller University, New York, as HFSP
|Denise Karaoglu Hanzatian, PhD||AbbVie|
Principal Research Scientist, Biologics Discovery, AbbVie Bioresearch Center
Denise Karaoglu Hanzatian, PhD, is a Principal Research Scientist at AbbVie Bioresearch Center. She received her PhD in Biochemistry and Molecular Biology from Clark University. She joined Abbott Laboratories (now AbbVie) to
lead Biologics efforts in immunogenicity assessment and bioanalytical testing of biotherapeutics in various disease indications. In addition, she has worked on several drug candidates, including the ones currently in clinical trials,
from different therapeutic areas such as immunology, neuroscience, and oncology. More recently, Dr. Karaoglu has been focusing on the targeting and delivery of biotherapeutics, especially, to CNS.
|David Karig, PhD||Clemson University|
Associate Professor, Systems and Synthetic Biology, Bioengineering
|Elena Karnaukhova, PhD||FDA|
Research Scientist, CBER
Dr. Elena Karnaukhova is a Research and Regulatory
Scientist with the Laboratory of Biochemistry and Vascular Biology, Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA). Prior to joining FDA in 2002, she was
a Principal Scientist with Starzent, Inc., VA and a Senior Research Scientist with Columbia University, NY. Her research interests include protein structure-function relationships and biophysical assessment, particularly with regards
to the proteins involved in conformational diseases and heme scavenging.
|Dennis Karthaus||IBA Lifesciences|
Dennis Karthaus received his master`s degree in biotechnology from
the University of Applied Sciences in Bremerhaven. During his thesis at the department of Pharmaceutical Biotechnology at the Fraunhofer Inst. for Toxicology and Experimental Medicine he worked on the development of protein purification
platforms and in cell line development. In 2012, Dennis Karthaus joined IBA Lifesciences. He is responsible for the mammalian custom protein expression & purification service and the product development in this field.
|Brian K. Kay, PhD||University of Illinois, Chicago|
Professor & Head, Biological Sciences,
Brian Kay is a world expert in the
field of molecular recognition, the science of how proteins selectively interact with each other. His current research group of 9 individuals utilizes phage-displayed libraries of combinatorial peptides, antibody fragments, and
engineered proteins to probe the surfaces of proteins and identify contact sites for binding. This approach is being currently applied to develop biosensors for protein kinases, create tools to study protein expression in cells
and organisms, generate affinity reagents to bacterial and human proteins, and develop diagnostics for monitoring laser-induced eye damage. He has authored 139 scientific reports and reviews, co-edited three books, and been issued
15 patents; he has an H-index of 56. He brings significant experience to this project in phage-display, library construction, screening combinatorial peptide libraries, generating recombinant affinity reagents with high affinity
and selectivity, technical trouble-shooting, and research leadership.
|Stubenrauch Kay-Gunnar, PhD||Roche|
Expert Scientist, Large Molecule Bioanalytical R&D
PhD, is an Expert Scientist, heading the department of “Large Molecule Bioanalytical Sciences 1” at Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich (Germany). He joined Roche Diagnostics
in 2000 and moved to Roche Pharma in 2003. Since then he worked in Large Molecule Research and Pharmaceutical Sciences. In his current position, his focus is on large molecule bioanalysis and immunogenicity testing. Kay has been
involved in several projects of therapeutic proteins and antibodies from preclinical up to in-market stages. Kay is a biochemist and received his PhD from Martin-Luther-University, Halle-Wittenberg (Prof. Rainer Rudolph) in 2000.
He has authored/co-authored numerous publications in the fields of large molecule research and bioanalysis including immunogenicity testing for biologics.
|Alex Kelly||Retrogenix Limited|
US Business Development Manager
Alex is responsible for growing Retrogenix’s North
American business portfolio and is based at Retrogenix's UK headquarters in the Peak District. Prior to joining the company, Alex spent two years at specialist pharmacogenomics service provider Epistem. Here he built successful
relationships with major pharmaceutical and biotech companies worldwide as part of his business development and lead generation role. Alex has a first class degree in Pharmacology with Industrial Experience from the University
of Manchester, UK.
|Ryan Kelly, PhD||xCella Biosciences|
Ryan completed his PhD in Biological Engineering at the
Massachusetts Institute of Technology under the guidance of Dane Wittrup. His thesis work focused on predicting and improving antibody developability and improving in vitro library designs. He now leads in vitro antibody development
efforts at xCella Biosciences.
|Saad Kenderian, PhD ||Mayo|
Assistant Professor, Medicine and Oncology,
The research of Saad J. Kenderian,
M.B., Ch.B., and his team is centered on the development and optimization of novel-engineered T cell therapy approaches for the treatment of cancer. Using the immune system to treat cancer (immunotherapy) has emerged as a potent
and potentially curative modality. The recent success of engineered T cell therapy highlights the potential for this technology as a new pillar in the treatment of hematological malignancies.
|Jennifer Kessler||MacroGenics, Inc.|
Senior Development Associate
Jennifer Kessler is a Senior Development
Associate at MacroGenics. She received her MS from the University of Maryland where she studied small chemical inhibitors of bacterial Type III secretion. Her current focus is analytical method development for process residuals
|Ulrich Kettling||CEVEC Pharmaceuticals GmbH|
Vice President, Business Development
Ulrich Kettling is Vice President Business
Development at CEVEC Pharmaceuticals. He has more than 18 years experience in executive and management roles in large industry, start-ups and as founder and entrepreneur in biopharma, protein therapeutics and synthetic biology.
He graduated in Biotechnology and obtained a PhD in Biophysical Chemistry at the Max Planck Institute, Germany.
|Bruce Keyt, PhD ||IGM Biosciences|
Bruce Keyt, Ph.D. CSO at IGM Biosciences has 35 years of R&D experience
in biotechnology. During 16 years at Genentech, worked on Factor VIII, tPA, TNKase, Avastin and Lucentis. At Millennium, built preclinical scientist team which helped develop Velcade and anti-PMSA. As VP of Abgenix preclinical,
Vectabix was approved as well as multiple INDs and corresponding clinical trials. As CTO, Trellis isolated human anti-RSV mAbs for Medimmune. Ph.D from Tufts University and B.S. in Chemistry from Washington Univ. Inventor on 35
patents and co-authored 55 articles.
|Philip M. Kim, PhD||University of Toronto|
Associate Professor, The Donnelly Centre for Cellular and Biomolecular Research, Departments of Molecular Genetics and Computer Science
Philip M. Kim is an Associate Professor at Donnelly Centre at the University of Toronto. He leads a research laboratory that integrates both computational and wet/experimental methods for biomedical sciences and drug discovery.
Before setting up his lab at the University of Toronto in 2009, he was a postdoctoral fellow at Yale University where he pioneered structural analyses of protein interactions networks and an associate with McKinsey & Co. He
holds a PhD from the Massachusetts Institute of Technology (MIT) and a BS in Biochemistry and Physics from the University of Tuebingen.
|Yong Sung Kim, PhD||Ajou University|
Professor, Molecular Science & Technology
Dr. Yong-Sung Kim has been
a professor of Dept. of Molecular Science and Technology at Ajou University (Suwon, Korea) since 2004. Dr. Kim received his B.Sc. in Food Science and Technology from Seoul National University in 1996. He obtained his M.Sc. in Biotechnology
in 1998 from KAIST and Ph.D. in Pharmaceutical Sciences in 2002 from the University of Colorado, Denver. After obtaining the Ph.D. degree, he joined the lab of Prof. K. Dane Wittrup at MIT as a post-doc for protein and antibody
engineering using yeast surface display. He spent one year (2010-2011) during his Sabbatical at Genentech Inc. (SF, USA), where he worked with scientists at Depts. of molecular oncology and antibody engineering. Dr. Kim’s
research focuses on development of next-generation antibody platform technology for diverse applications, including heterodimeric Fc-based bispecific antibody, solid tumor-penetrating antibody, and cytosol-penetrating antibody
to address cytosolic proteins. Dr. Kim has transferred 4 antibody-related platform technologies developed in his lab to several Korea-based and USA-based companies. Particularly, Dr. Kim co-founded ORUM Therapeutics Company with
Dr. Sung-Joo Lee in 2016 for the commercialization of cytosol-penetrating antibody technology. His website is http://antibody.ajou.ac.kr/.
|Kei Kishimoto, PhD||Selecta Biosciences|
Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences,
a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary
teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development,
and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.
|Scott L. Klakamp, PhD||Janssen BioTherapeutics |
Senior Director & Head, Biophysics, Biologics Development Sciences
Dr. Scott Klakamp is the Sr. Director and Head of Biophysics at Janssen R&D, LLC. Dr. Klakamp is one of the leading scientists in utilizing Biacore® and KinExA® to measure the binding kinetics and equilibrium dissociation
constants of human monoclonal antibody/antigen complexes. Prior to Janssen, Dr. Klakamp was the Founder and Principal Consultant of SKD Consulting LLC. Before SKD Consulting, he was the Vice President of Chemistry and Biochemistry
at BiOptix Inc. Dr. Klakamp has also held positions of increasing responsibility in the areas of analytical and biophysical characterization at Chiron, Amgen/Abgenix, AstraZeneca/MedIummune, and Takeda Pharmaceuticals. Dr. Klakamp
has been an author on over 30 research and review papers, book chapters, and patents, and has coedited two books dealing with translational monoclonal antibody research. He has also been an invited speaker at numerous international
and national meetings. Dr. Klakamp received his B.A. in Chemistry from Houghton College and his PhD in Chemistry at the Pennsylvania State University. From 1990 to 1993, he completed a postdoctoral fellowship (funded by a National
Research Service Award from the National Institutes of Health) at the California Institute of Technology in bioinorganic chemistry.
|Christian Klein, PhD||Roche Innovation Center, Zurich|
Oncology Discovery & Translational Area, Cancer Immunotherapy Discovery, PRED
Christian Klein, Distinguished Scientist is Head of Oncology Programs and Department Head Cancer Immunotherapy Discovery at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Switzerland
specialized in the discovery, validation and preclinical development of antibody-based Cancer Immunotherapy (CIT) and bispecific antibodies. During his >14 years at Roche he has made major contributions as research project leader
to the development and FDA/EMA approval of GAZYVA/GAZYVARO (obinutuzumab, GA101), to the preclinical development of five bispecific antibodies currently in active clinical development: 1) anti-Ang-2/VEGF CrossMAb RG7221 (vanucizumab)
in oncology (Ph II), 2) anti-VEGF/Ang-2 CrossMAb RG7716 in ophthalmology (Ph II), 3) CEA-IL2v immunocytokine RG7813 (Ph I), 4) CEA-CD3 T cell bispecific antibody (CEA TCB) RG7802 (Ph I), 5) FAP-IL2v immunocytokine RG7461 (Ph I),
and lead the development of Roche’s novel bispecific antibody technologies e.g. the CrossMAb, immunocytokine and T cell bispecific antibody platforms. Since 2012 he is doing his “Habilitation” in Biochemistry
at the Ludwig-Maximilians University (LMU) in Munich, Germany.
|Hans Klingemann, PhD ||Nantkwest|
Vice President, Research and Development,
Dr. Klingemann has served as
the company’s Vice President of Research & Development since joining full time in 2012. He is also the discoverer of the NK-92 cell line and co-founder of the company. Prior to joining NantKwest, Dr. Klingemann served
as the Director of the Bone Marrow and Stem Cell Transplant Program and the Director for Hematological Malignancies at Tufts Medical Center in Boston. He also served as Director of the Section of Bone Marrow Transplant & Cell
Therapy at Rush University Medical Center in Chicago where he established the first clinical GMP Cell Therapy facility in the Chicago area. He maintains an academic appointment at Tufts University Medical School.
|Emilee Knowlton||ProImmune Inc.|
Immunology Sales Specialist
Emilee gained her PhD in Infectious
Diseases and Microbiology from the University of Pittsburgh under the direction of Prof. Charles Rinaldo, identifying immune responses to lytic infection with Human Herpes Virus-8. She joined ProImmune in 2013 after completing
her Post Doc in Rinaldo’s lab. She works on the ProImmune team providing innovative solutions for clients that radically improve our understanding of both desired and unwanted immune responses.
|Luke Koblan, PhD||Harvard University|
Scientist, Chemical Biology, Chemistry & Chemical Biology
is a student in David Liu’s lab. Before his time in the Liu Lab, he worked for both Jay Bradner developing cell-based assays for targeted bromodomain inhibition and Todd Golub on a serine protease-profiling project. These
experiences led to an interest in using technology development as a platform to illuminate new biology. His current work is focused on improving current base editing technologies and developing novel editors. He is supported by
an NSF GRFP fellowship.
|Sergii Kolodych, PhD||Syndivia|
Dr. Kolodych is a co-founder and Chief Scientific Officer of Syndivia,
a company committed to the development of disruptive cancer therapeutics. Prior to joining Syndivia, Dr. Kolodych worked on the development of novel bioconjugation technologies at the University of Strasbourg and in French Atomic
Energy Commission (CEA Saclay)
|Roland Kontermann, PhD||University of Stuttgart|
Professor of Biomedical Engineering, Institute of Cell Biology and Immunology
Roland Kontermann holds a PhD in Molecular Biology from the University of Heidelberg. After working as a postdoc in the laboratory of Sir Gregory Winter at the MRC Centre for Protein Engineering, Cambridge, UK, he was group leader
at the Institute of Molecular Biology and Tumor Biology of the University of Marburg, and subsequently Head of Research at vectron therapeutics AG. Since 2004, he was Professor of Biomedical Engineering at the Institute of Cell
Biology and Immunology of the University of Stuttgart, Germany. Current research focuses on the development of recombinant bispecific and bifunctional antibody molecules, including half-life extension strategies, for tumor therapy
and treatment of inflammatory and neurodegenerative diseases.
|Serguei Kozlov||Frederick National Laboratory for Cancer Research (NCI)|
Principal Scientist/PM, Team Leader PTO, Center for Advanced Preclinical Research
Internationally recognized expert in advanced methodologies for developing genetically and biologically engineered preclinical murine disease models for studies of the molecular mechanisms of carcinogenesis, tumor immune response,
immune surveillance, and inflammation, mechanisms of drug resistance, implication of cancer stem cells, etc.; and to explore such models for preclinical drug development, disease systems analyses and biomarker discovery. Initiated,
supervised, and successfully conducted multiple research projects and independent large-scale research and development programs aimed at investigation of molecular mechanisms governing carcinogenesis, biomarker discovery and preclinical
drug evaluation in various mouse models. Oversee the preclinical operations at the Frederick National Laboratory Center for Advanced Preclinical Research – an innovative preclinical cancer modeling and drug development initiative
based on genetically engineered murine models – with senior management responsibilities. Co-authored over 60 scientific papers, book chapters and original works in peer-reviewed journals.
|Michael Krogh Jensen, PhD||Novo Nordisk Foundation Center for Biosustainability|
Senior Researcher & Co-Principal Investigator, Technical University of Denmark
Dr. Michael Krogh Jensen from DTU will be the Coordinator of the MIAMi project. Dr. Krogh Jensen has extensive experience with project management in both national and international collaborative projects, including his formal
roles as Dissemination Manager in HZ2020 program PAcMEN, Co-Coordinator on an international DNA synthesis project founded by the Joint Genome Institute (US), and numerous international research collaborations with visiting researchers.
Scientifically, Dr. Krogh Jensen is an expert on the development of synthetic biology tools for yeast, with training obtained from renowned laboratories in Europe (Max-Planck Institute, Cologne, Germany) and the US (Stanford University,
Palo Alto, USA). In 2007, he obtained his PhD in molecular biology from the University of Copenhagen, Denmark. From 2008 to 2011, he held independently funded postdoctoral research grants managing international collaborations within
transcriptional regulation, and from 2012 to 2013, he headed a collaboration on genome-wide protein-protein interactions between University of Copenhagen and Stanford University. Since 2013, Dr. Krogh Jensen has been Co-Principal
Investigator together with Scientific Director Prof. Jay D. Keasling in the Section for Synthetic Biology Tools for Yeast at the Novo Nordisk Foundation Center for Biosustainability (CfB) at DTU with daily responsibility of 13
international scientific and technical staff members. During this period, Dr. Krogh Jensen has led the development of the CRISPR/Cas9 toolkit for yeast, the development of biosensors, DNA parts characterization, and refactoring
and prototyping of MIA pathway designs in yeast. He is a co-author of 34 peer-reviewed publications with an h-index of 17 and more than 1200 citations. He is also co-inventor of a patent on the design of biosensors in eukaryotes.
|Pabuddha Kundu, PhD||Premas Biotech Pvt Ltd|
Co-Founder & Managing Director
Prabuddha is one of the co-founders of Premas Biotech
along with his colleagues in 2005. He has over 20 years of experience in Biotech and Pharma Industry. Prior to joining industry, he obtained in PhD in Biomedical Engineering, with specialization in antibody manufacturing and scale
up. He holds 8 patents, 20 publications and is part of of governmental bodies, corporate think tanks and academic institutions. His interests are mainly with increasing operational efficiencies, reducing cost of goods, and novel
|Andreas Kungl, PhD||Antagonis Biotherapeutics GmbH|
Andreas was born on 13. April 1964 in Vienna, where he studied Biochemistry
from 1982-1988 receiving his PhD in 1991. He was then awarded a Schrödinger Fellowship to do his Post-Doc studies in protein structure-function relationships at the Max-Planck-Institute of Biochemistry under Robert Huber.
From 1993-1997 he was working as a researcher (later as senior scientist) at the Sandoz-/later Novartis-Research-Institute in Vienna performing biophysical investigations of drug-receptor interactions. After receiving an Austrian
Academy of Sciences fellowship to promote the interaction between basic and applied research, he became Associate Professor for Biophysical Chemistry at the Institute of Pharmaceutical Chemistry in Graz. In 2005 Andreas co-founded
ProtAffin Biotechnology AG, a privately-held biotech company located in Graz and in London, which developed novel, chemokine-based biopharmaceuticals for inflammatory applications such as COPD. In 2011, he was appointed Professor
for Biopharmaceuticals and Proteomics at the Institute of Pharmaceutical Sciences in Graz. In March 2015, Andreas co-founded his second biotech company, Antagonis Biotherapeutics GmbH, where he currently holds the CEO position.
Antagonis develops novel glycan-targeting biologics in the field of immune-oncology.
|Christian Kunz, PhD||MorphoSys AG|
For almost 10 years, Dr. Kunz is working as Project Team Leader
at MorphoSys in early discovery projects in order to develop therapeutic antibodies for various oncological indications. In his team the work is focused on immuno-modulatory agents that improve therapeutic responses through immune
engaging bispecific compounds. Throughout the years, he and his team successfully identified, characterized and engineered multiple antibody lead candidates, handed them over to preclinical departments where they further progressed
into clinical studies.
|Vinodh Kurella, PhD ||Merrimack Pharmaceuticals|
Principal Scientist, Protein Engineering
Vinodh Kurella is a protein engineer
with a focus on antibody and antigen designs via structure guided computational modeling-based approach. Before joining Merrimack Pharmaceuticals, he was team lead for CAR-T designs, engineering and validations in the Immuno_Oncology
division at Intrexon Corporation. He completed his post-doctoral training at Dana Farber Cancer Institute and Harvard Medical school in Dr. Wayne Marasco laboratory and received Ph.D. in Dr. David Worthylake lab from Dept. of Biochemistry
at LSU Health Sciences Center in the field of protein X-ray crystallography.
|Jonathan R. Lai, PhD||Albert Einstein College of Medicine|
Professor, Department of Biochemistry
Jonathan Lai is Professor of Biochemistry
at the Albert Einstein College of Medicine in the Bronx, NY. Dr. Lai received his undergraduate training in Biochemistry at Queen’s University in Kingston, Ontario, Canada, then obtained his PhD in Chemistry and Biophysics
at the University of Wisconsin, Madison in 2004. From 2004-2007, he was Helen Hay Whitney Post-Doctoral Fellow in Biological Chemistry at Harvard Medical School. He began his independent lab at the Albert Einstein College of Medicine
in 2007. His group has broad interests in peptide, protein, and antibody engineering with application of these methods to discovery of new immunotherapies and vaccines.
|Jane Lamerdin, PhD||Eurofins Pharma Discovery Services|
Director, Research & Development
Dr. Lamerdin leads a diverse group
of scientists responsible for the development of novel cell-based assays for discovery as well as qualification of bioassays for lot release and neutralizing antibody applications. Jane has over 19 years of experience in industry
generating cell-based assays to support large and small molecule drug discovery, particularly in the oncology, immune-oncology and inflammation therapeutic areas. She received her Ph.D. from the University of California, Davis
in Genetics, and has broad expertise in molecular and cellular biology, systems biology/signal transduction, high throughput screening, high content imaging, and diverse reporter and phenotypic assay formats.
|Martine LM Lamfers, PhD||Erasmus Medical Center|
Assoc Professor, Neurosurgery, Brain Tumor Center
Dr Lamfers heads the
Neurosurgery Laboratory at Erasmus MC. Her lab is focused on the development of novel treatments for malignant glioma using innovative patient-derived model systems. These treatments include novel compounds, drug repurposing strategies
and oncolytic viruses. She set up a drug development pipeline encompassing biobanking of patient tissue and PBMCs, derived cell cultures/tumor organoids, in vitro 2D and 3D drug screening and in vivo validation. Her goal is to
implement such model systems for predicting response to therapy and/or selecting the most optimal treatment for a specific patient. She was also involved in the preclinical development of the oncolytic adenovirus Delta24-RGD (DNX2401),
studying its oncolytic and immunotherapeutic potential in various in vivo models as well as in a trial-associated study on the immune response to local Delta24-RGD infusion in recurrent glioblastoma patients.
|David Lansky, PhD||Precision Bioassay, Inc.|
David has been learning and practicing statistics for bioassays
and other non-clinical applications in Pharma for 30 years. This includes 10 years at Searle/Monsanto/Pharmacia and 16 years as the owner of Precision Bioassay, Inc. David has been and is still an active participant in the work
to revise the USP bioassay chapters. His education includes a year of Electrical and Computer Engineering (University of Michigan), a BS in Botany (San Francisco State), an MS in Entomology (Cornell) and finally both an MS and
Ph.D. in Biometry (both Cornell).
|Holger Laux, PhD||Novartis Institutes for BioMedical Research|
Fellow, Cell Line Development
Dr. Laux is leading the cell line development
network of “Biologics Technical Development & Manufacturing” within Novartis. Throughout his career he focused his work on functional genomics approaches as transcriptomics screens and subsequently cell line engineering
editing. These efforts resulted in generation of several improved CHO production cell lines. He was also supporting the sequencing of Chinese hamster resulting in a public available Chinese hamster genome. He is additionally involved
in enabling and improving the production of difficult to express therapeutic recombinant proteins.
|Sean Lawler, PhD||Brigham and Women's Hospital|
Asst Professor, Managing Director, Harvey Cushing Neurosurgery Laboratories
No bio available
|Robert J. Lechleider, MD||Seattle Genetics|
Senior Vice President, Clinical Research
Robert J. Lechleider, M.D.
is Senior Vice President, Clinical Development at Seattle Genetics where he is responsible for directing development of the early and late stage portfolios. Previously, Dr. Lechleider held key roles at several biopharmaceutical
companies, including MacroGenics and MedImmune. Before joining the biotechnology industry, he served as Assistant Professor of Pharmacology at Uniformed Services University of the Health Sciences, and Associate Professor of Cell
Biology at Georgetown University Medical School. Dr. Lechleider received his A.B. cum laude from Princeton University and his M.D. from the University of Illinois College of Medicine at Chicago. He received clinical training in
internal medicine at Beth Israel Hospital in Boston and in medical oncology at the National Cancer Institute in Bethesda. He was also a Howard Hughes Medical Institute Scholar and a Damon Runyon-Walter Winchell postdoctoral fellow.
|Sun Bae Lee, PhD||Alteogen|
Senior Research Scientist
Education and Experience: 1. Senior Research Scientist,
Alteogen Inc. Daejeon, Korea, May 2012 ~ present; 2. Research Scientist, Division of Medicinal Chemistry, University of Texas at Austin, Texas; 3. Postdoctoral Fellow, Department of Biochemistry and Biophysics, Texas A&M University,
Texas; 4. Ph. D., School of Chemistry, Seoul National University, Seoul, Korea; 5. BA & MS, School of Chemistry, Seoul National University, Seoul, Korea.
|James Legg, PhD ||Crescendo Biologics|
Vice President, Research and Development,
James Legg Ph.D is SVP Research at
Crescendo Biologics where he is responsible for managing Crescendo’s Immuno Oncology Portfolio from research through to preclinical development as well as the biology/pharmacology functions. James has 15 years’ experience
in biologics drug discovery, mostly in the oncology area and has been responsible for the successful progression of multiple oncology biologics programmes through the research phases of drug discovery. Prior to joining Crescendo,
James was a member of the oncology leadership team at MedImmune, the Biologics arm of AstraZeneca and held key scientific positions at Cambridge Antibody Technology.
|Hans-Georg Lerchen, PhD||Bayer AG|
Chief Scientist, R&D Pharmaceuticals
Hans-Georg Lerchen is Chief
Scientist in the Medicinal Chemistry unit of Pharmaceuticals R&D at Bayer AG. With a 30 years background in MedChem he is author or co-author of ~79 patents or patent applications and 19 publications. His current research focus
is drug delivery systems, prodrugs and in particular antibody drug conjugates.
|Xiaojuan Li, PhD||Merck & Co., Inc|
Associate Principal Scientist, Protein Mass Spectrometry Department
Xiaojuan Li, PhD, Associate Principal Scientist, Protein Mass Spectrometry Department, Merck & Co., Inc. More than seven years of biopharmaceutical industry experience with LC-MS method development for biologics characterization
and in-process support.
|Zonghai Li, PhD ||CARSgen|
CEO and CSO
Zonghai Li,MD, Ph.D., Founder, CEO and CSO of CARsgen Therapeutics,
a leading company on CAR-T cell therapeutics in China. Dr. Li is a professor in Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine. Dr. Li got his M.D. and Ph.D. from Hunan Medical University
and Fudan University respectively. Dr. Li is dedicated to developing innovative immune therapeutics to fight cancer. He has advanced several first-in-class CAR-T cell therapeutics for the treatment of patients with pancreatic,
gastric, liver cancer and other cancer types.
|Jasper Lin, PhD||Genentech|
Scientist and Group Leader
Jasper Lin graduated from University of Washington in
Seattle with a Ph. D. in biophysical chemistry. His early work focused on higher order structure of proteins and how it relates to protein folding. After a post-doctoral position at the Puget Sound Blood Center Research Institute
(now called Bloodworks), he joined Roche/Genentech in the Late Stage Pharmaceutical Development department. He currently is a Scientist and Group Leader in Early Stage Pharmaceutical Development.
|Qingcong Lin, PhD||Biocytogen Boston Corp|
Dr. Qingcong Lin is CEO of Biocytogen Boston, focusing on developing
gene-specific humanized mouse models for immuno-oncology drug candidate preclinical pharmacology and toxicity assessment. Dr. Lin was SVP of Shenogen Pharma Group, responsible for biologic drug development. Before Joining Sheongen,
he was a Principal Scientist at Pfizer and led antibody engineering group. Dr. Lin received Ph.D. degree from Albert-Einstein College of Medicine and completed postdoctoral training at Harvard Medical School.
|Thomas Little, PhD||Bioassay Sciences, Thomas A. Little Consulting|
President and CEO
Thomas Little, PhD, President and CEO, Bioassay Sciences,
Thomas A. Little Consulting Dr. Little is President of BioAssay Sciences (BAS) a globally recognized bioassay consulting company for biologicals and vaccines. BAS specializes in the design, calculation and control of potency and
relative potency for bioassays. BAS specializes in In-Vivo and In-Vitro bioassays. BAS works with international companies and health authorities globally to achieve product development goals aligned to ICH and USP guidance. BAS
is a strategic partner of SAS/JMP and a division of Thomas A. Little Consulting. Dr. Little has developed specific content courses in statistical methods and data analysis, Bioassay Design and Validation, Quality Risk Management,
design of experiments, Robust Optimization, Design Space and Tolerance Design, Assay Development and Method Validation, statistical process control, mixture design of experiments, Stability Analysis and Nonlinear Modeling. These
courses are used by a variety of fortune 100+ companies to train their chemists, engineers and scientists.
|David V. Liu, PhD||Abbvie|
Director, Protein Engineering
David Liu is the Director of Protein Engineering
at Abbvie, where he focuses on antibody and protein engineering for antibody drug conjugates and other antibody-based therapeutics against cancer stem cell targets. David completed his PhD in Dane Wittrup’s lab at MIT
|Liming Liu, PhD||Merck Research Laboratories |
Senior Principal Scientist, Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM)
Dr Liu obtained his Ph.D. in immunology at University of Oxford followed by several years’ postdoc work at Harvard University before working in biotech industry in early 2000. Dr Liu has extensive experience in the discovery
and development of mAbs and Fc-fusion proteins. He was the head of Immunology group of Syntonix Pharmaceuticals (acquired by Biogen, then Sanofi), working on mAb and Fc-fusion molecule discovery programs. He joined Merck Pharmacokinetics,
Pharmacodynamics and Drug Metabolism (PPDM) department in 2007 and have worked on more than a dozen Merck Biologics programs including monoclonal antibodies and Fc-fusion proteins from discovery to development and regulatory filings.
|Deryk Loo, PhD||MacroGenics, Inc.|
Director, Targeted Therapeutics and Site Operations
Deryk Loo is the Director
of Targeted Therapeutics and Site Operations at the Brisbane site of MacroGenics, Inc., which he joined in 2008 following the acquisition of Raven biotechnologies, Inc. Dr. Loo has been active in drug discovery and development
for the past 15+ years, focusing on antibody-based therapeutics, and more recently antibody drug conjugates. Dr. Loo has authored numerous publications in the field of oncology and is an inventor on several patents.
|James Love, PhD||Institute for Protein Innovation|
Chief Operating Officer
James Love was educated at Oxford and Cambridge Universities,
and was trained as a structural biologist at the MRC-LMB. In New York, Dr. Love was the Head of Research for the New York Consortium on Membrane Protein Structures, which utilized high throughput protein production methods to express,
purify and screen thousands of integral membrane proteins for structural studies. Dr. Love then developed high throughput expression and purification techniques for eukaryotic and oxygen sensitive proteins at Albert Einstein College
of Medicine, before joining ATUM (formerly DNA2.0) as Director of Expression Technologies. Dr. Love is also an executive editor of the journal “Protein Expression and Purification”. At the Institute for Protein Innovation,
Dr. Love is building platforms for production of all human cell surface proteins, including integral membrane proteins, and specific antibodies that bind to these targets.
|Emily Lowe, PhD||Kite Pharma, a Gilead Company|
Senior Scientist, Analytical Sciences
Dr. Emily Lowe is multidisciplinary scientist
with 15 years of research experience in immunology and host-pathogen interactions. She is currently a Senior Scientist at Kite Pharma, a Gilead company, where she has been leading the Bioassay Team since 2015 to develop cell-based
potency assays in the Analytical Development group within the Product Sciences department. Prior to joining Kite, Dr. Lowe worked in Dr. Jerome Zack’s laboratory at UCLA where she helped to develop “induction/kill”
strategies to eradicate HIV reservoirs in vivo using genetically engineered immunity and the humanized mouse model. During her PhD studies into innate immunity and inflammation, Dr. Lowe split her time between the laboratories
of Dr. Genhong Cheng (UCLA) and Dr. Moshe Arditi (Cedars-Sinai) where she discovered that Toll-like Receptor 2 played a protective role in both the epithelial and immune compartments during the development of colitis-associated
colorectal cancer. Dr. Lowe’s passion for immunology began at the University of Washington where she completed two B.S. degrees, one in Microbiology and one in Biochemistry.
|Eline T. Luning Prak, MD, PhD||University of Pennsylvania|
Associate Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine
Dr. Luning Prak is an associate professor of Pathology and Laboratory Medicine at the University of Pennsylvania. She runs a research lab that studies immune repertoires and B cell subsets in humans. She also directs the Human
Immunology Core facility at Penn, which performs immune repertoire profiling experiments for dozens of investigators each year. She is chair elect of the Adaptive Immune Repertoire Community (AIRR-C), an international group of
investigators, legal experts and others interested in immune repertoire profiling by next-generation sequencing-based methods.
|Robert Lutz||Crescendo Biopharma Consulting|
Bob has been an independent consultant in the biotech/pharma
industry since 2015 and has worked with multiple clients providing strategic, tactical and operational input for their research and development efforts. Prior to initiating his consulting practice, Bob held various R&D roles
over a 23 year span at ImmunoGen, Inc. In his most recent position at ImmunoGen, Bob was Vice President of Translational Research and Development with responsibility for all early stage antibody drug conjugate (ADC) development
programs from lead identification through phase 2. He also served as ImmunoGen’s research lead on Genentech’s FDA-approved trastuzumab emtansine (T-DM1) program. Before the ADC research position, Bob was part of ImmunoGen’s
Apoptosis Technology Inc subsidiary where he led the research collaboration leading to the discovery of the BH3 domain of the BCl-2 family of death regulatory proteins. Before ImmunoGen, Bob was a research and postdoctoral fellow
at the Eleanor Roosevelt Institute in Colorado. He earned his doctoral degree in Biochemistry at Brandeis University.
|Robert Mabry, PhD||Takeda|
Lead, Biologics Research Group
Biotechnology leader with over a decade of
experience working with large pharma, biotech companies, and venture-backed startups. Extensive experience managing teams in multiple therapeutic areas and a demonstrated track record of accelerating leads into preclinical development.
|Loui Madakamutil, PhD ||Nektar |
Vice President, Head of Discovery
Loui Madakamutil is VP and Head of
Discovery and Research at Nektar Therapeutics. In this role Loui is responsible for the discovery strategy of Nektar to deliver novel immuno-modulatory medicines in several therapeutic areas. Previously Loui was a Senior Director
at J&J. Loui held appointment as the Site Head of Immunology at Takeda Pharmaceuticals in San Diego. Loui also spent five years in Immunology discovery at Celgene. He has taken several large and small molecule compounds into
clinic. Loui did his Post-Doctoral training at the La Jolla Institute for Allergy and Immunology and has a PhD from University of Mumbai India.
|Sheila G. Magil, PhD||BioProcess Technology Consultants, Inc.|
Sheila Magil, Ph.D., Senior Consultant withBioProcess
Technology Consultants, has over 35years of experience in quality,bioanalytical and analytical method development for biologics, peptides andsmall molecules. Her expertise includes qualitycontrol and assurance, protein and peptide
biochemistry, and analyticaldevelopment. She was formerly SeniorManager of Analytical Development and Quality Control at Biomeasure, Inc., and previously held positions at Waratah Pharma, Alkermes, Bion, and HHMI at MassachusettsGeneral
Hospital. Dr. Magil has implemented quality systems and has managed external analytical and QC activities for multiple biopharmaceutical products. Dr. Magil holds a Ph.D. in Biochemistry from the University of Minnesota.
|Maksim Mamonkin, PhD ||BCM|
Assistant Professor, Center for Cell and Gene Therapy
Dr. Mamonkin is a faculty
member at the Center for Cell and Gene Therapy, Baylor College of Medicine. Main research focus of his laboratory is the mechanisms and effects of CAR and TCR signaling in therapeutic T cells and developing new CAR-based approaches
combined with genome editing and synthetic biology for the targeted therapy of aggressive hematologic malignancies and auto/alloimmune complications. Dr. Mamonkin developed and optimized CD5- and CD7-directed CARs for clinical
evaluation in T-cell malignancies and AML. He serves as a PI on several ongoing and upcoming clinical trials of CAR T cells in hematologic malignancies at Baylor.
|Araya Marcela, PhD||Pfizer|
Principal Scientist, Group Leader, BioMedicine Design
Dr. Marcela Araya
is currently a Principal Scientist/Group Leader in the Department of BioMedicine Design at Pfizer. She leads a group that provides regulated bioanalytical support including assay development, validation and sample analysis for
non-clinical and clinical PK and immunogenicity assays. She received her Ph.D in Nutritional Sciences from the University of Illinois at Champaign-Urbana. She then completed her postdoctoral work at the GLP Bioanalytical Core Laboratory,
Department of Pharmaceutics in Virginia Commonwealth University (VCU), where she developed and validated methods for small molecule drugs. Prior of joining Pfizer, Dr. Araya spent numerous years at PPD (CRO) in their Immunochemistry
|John R. Mascola, MD||NIH|
Director, Vaccine Research Center, National Institute of Allergy and Infectious Diseases
Dr. John Mascola is Director of the Dale and Betty Bumpers Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health. His background is in infectious diseases,
viral immunology and vaccine research. His research focuses on antibody-mediated protective immune responses through studies of both the plasma antibody and B-cell compartments, including studies to understand the genetic and immunological
characteristics that guide the development of broadly neutralizing antibodies against viral pathogens.
|Yariv S. Mazor, PhD||MedImmune|
Senior Scientist, Antibody Discovery & Protein Engineering
Dr. Yariv Mazor
joined MedImmune in 2009; he is leading the antibody discovery group at the Department of Antibody Discovery and Protein Engineering and co-leads multiple antibody bio-therapeutic programs into clinical development. Yariv received
his PhD in Biotechnology from Tel-Aviv University, Israel in 2005, where he studied and developed antibody therapeutics and antibody-drug conjugates for cancer. He then pursued postdoctoral training at the Dept. of Chemical Engineering,
University of Texas at Austin, TX under Prof. George Georgiou where he developed a novel platform for the selection and screening of engineered full-length IgG antibodies from libraries expressed in E. coli. Yariv is the co-inventor
5 patents or patent applications and the author of 20 peer-reviewed papers.
|Charlotte McDonagh, PhD||Magenta Therapeutics|
Vice President, Head of Biotherapeutics
Charlotte McDonagh joined Magenta
Therapeutics in 2017 as Head of Biotherapeutics. She previously served as a vice president at Merrimack Pharmaceuticals, where she led discovery and early clinical stage programs. Prior to joining Merrimack, she led therapeutic
antibody selection and engineering projects at Seattle Genetics. Charlotte holds a doctorate in biochemistry from the University of Leicester, U.K, and an undergraduate degree in biochemistry from the University of Bristol, U.K.
|Kathleen McGuiness, PhD ||Unum Therapeutics|
Senior Director, Platform Technologies,
Kathleen McGinness is the
Senior Director of Platform Technologies at Unum Therapeutics. Unum is discovering and developing new cellular immunotherapies for cancer using its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology. Kathleen is responsible
for inventing and evaluating new technologies that direct patient-derived immune cells to destroy cancer cells. Prior to Unum, Kathleen served in roles at the Broad Institute, Baxter Healthcare, and Archemix Corp. focused on target
validation, drug discovery, and therapeutic platform development across a variety of therapeutic modalities and disease areas. She holds B.S. degrees in chemistry and psychology from the University of Maryland, a doctoral degree
in chemistry from The Scripps Research Institute, and completed postdoctoral training in the department of biology at MIT.
|Sarah McWhirter, PhD ||Aduro|
Director, STING Research,
No bio available
|Sebastian Meyer, PhD||Numab Innovation AG|
Sebastian is Chief Operating Officer of Numab Innovation, a Swiss
biotech company with partnered as well as proprietary pipeline assets in the field of immuno-oncology and inflammatory diseases. Prior to joining Numab, Sebastian headed the downstream processing and analytics unit of ESBATech,
focusing on process development and characterization of novel scFv drug candidates in Phase I/II of clinical development, including RTH258 (brolucizumab). Prior to that, Sebastian was a group leader in bioprocess development at
Cytos Biotechnology. Sebastian holds a degree in Biochemistry from the University of Hamburg and a PhD from the University of Zurich.
|Stephen D Miller, PhD||Northwestern University|
Dr. Stephen Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology
at Northwestern University Feinberg School of Medicine in Chicago. He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining
the faculty at Northwestern in 1981 where he currently serves as Director of the Northwestern University Interdepartmental Immunobiology Center. Dr. Miller is internationally recognized for his research on pathogenesis and regulation
of autoimmune diseases. He has published over 400 journal articles, reviews and book chapters and has trained multiple generations of scientists. His work has significantly enhanced understanding of immune inflammatory processes
underlying chronic autoimmune disease employing animal models of multiple sclerosis (MS) and Type 1 diabetes (T1D). His work has focused on the study of the cellular and molecular mechanisms underlying treatment of established
T cell-mediated autoimmune diseases using antigen-specific immune tolerance. His current work is geared to translating the use of antigen-linked biodegradable PLG nanoparticles for the treatment of human immune-mediated diseases
including autoimmunity, allergy and tissue/organ transplantation.
|Shahram Misaghi, PhD||Genentech, Inc.|
Senior Scientist, Early Stage Cell Culture
I am a senior scientist at
Genentech and have been part of the Cell Culture department since 2010. My research involves improving/innovating processes that result in generation of cell lines expressing bio-therapeutics (proteins and antibodies used as drugs)
at high titers and with specific product quality attributes. Bachelors: University of California Berkeley, Molecular and Cell Biology. PhD: Harvard University, in Biological and Biomedical Sciences. Post-doctoral fellow at Massachusetts
Institute of Technology (MIT) and Genentech
Senior Research Associate, Antibody Discovery
Alexey Misorin is a Senior
Research associate in the Display method laboratory of Antibody Discovery Division. Alexey received a master degree in Biophysics at St. Petersburg State University in 2014. From 2015, he works in Biocad, with a focus on the application
of methods that allow providing the kinetic analysis and characterization of antibodies.
|Arturo Molina, MD||Sutro Biopharma Inc.|
Experienced Chief Medical Officer with a demonstrated history of working
in the biotechnology industry. Skilled in Pharmaceutics, Biomarkers, Translational Medicine, Oncology, and Hematology. Strong healthcare services professional graduated from Stanford University School of Medicine. Practicing oncologist/hematologist,
volunteer staff physician at the Palo Alto VA Hospital, a Stanford-affiliate teaching hospital.
|Céline Monnet, PhD||LFB Biotechnologies|
Head of Laboratory, Research
Dr Céline Monnet is a molecular and
cellular biologist. She obtained her PhD from Paris-Sud University, specializing in antibody engineering and phage display screening processes at the CEA/bioMérieux research center (Saclay, France). After 5 years of academic
research in neurobiology and neurovirology, she spent 7 years at MilleGen SA (Toulouse, France) as head of the Therapeutic Antibody Development Platform. In November 2013 she joined LFB Biotechnologies (Lille, France) and is now
head of the Molecular Evolution Group in charge of antibody engineering and phage display screening.
|William C. Motel, PhD||IQVIA Global Regulatory Affairs|
Director, Regulatory Affairs
William leads the orphan drug unit within GRA
and serves as the US Agent for multiple Investigation of New Drugs, New Drug Applications and Supplements. William provides strategic advice to clients on regulatory strategy, leads regulatory projects and specialty designation
requests, provides CMC technical writing and reviews for new applications (INDs, NDAs, BLAs) in rare disease space; interacts with Regulatory Agencies (FDA, Heath Canada, etc.) He has also served as the Regulatory Project lead
for numerous NDA 505(b)(2) applications approved by the US FDA.
|Hatim Motiwala, PhD||Enzene Biosciences Limited|
Head, Cell Line Engineering and Bio-Analytical Sciences
Dr. Hatim Motiwala has completed
his PhD in Microbiology as a part of industry-academia partnership between The Maharaja Sayajirao University of Baroda and Intas Pharmaceuticals Limited, India. He has 18+ years of experience working in biopharmaceutical industry
with specialty in mammalian cell culture and bioanalytics. He has worked with some of top biotech company in India such as Intas Pharmaceuticals, Biocon and Sun Pharma. He is heading Cell Line Engineering (CLE) and Bio-Analytical
Sciences (BAS) groups at Enzene Biosciences Limited, India. He was involved in commercial launch of biosimilar proteins and mAbs.
|Liviu Movileanu, PhD||Syracuse University|
Liviu Movileanu has received the Ph.D. degree in biophysics
from the University of Bucharest (1997). He has acquired postdoctoral positions at the University of Missouri (Kansas City, USA, 1997-1998) and the Texas A&M University Health Science Center (College Station, Tex, USA, 1999-2004).
He is also affiliated to Syracuse Biomaterials Institute (SBI), SUNY Upstate Cancer Research Institute, and Institute of Complex Adaptive Matter (ICAM-I2CAM). Currently, his research group is funded by the US National Institutes
of Health. His expertise areas include single-molecule and membrane biophysics, chemical and synthetic biology, bionanotechnology and nanomedicine, biosensors and functional biomaterials, biological statistics, and numerical analysis
of stochastic biological processes.
Scientist, Development, Analytical Sciences
My name is Ashley Mullan, I
have a Bachelor of Science in Biology and a Master of Science in Biotechnology from University of Maryland. I am a scientist currently working in Bioassay Development at MedImmune located in Gaithersburg, Maryland. I have been
developing Bioassays at MedImmune for 10 years utilizing both binding and cell-based assay platforms. I am responsible for bioassay development for a variety of molecule types, including fusion proteins, ADCs and more recently
|Smita Nair, PhD||Duke University School of Medicine|
Professor, Surgery, Neurosurgery and Pathology
Smita Nair, PhD, is a Professor
of Surgery, Neurosurgery and Pathology at Duke University School of Medicine and member of the Duke Cancer Institute (DCI) and the Brain Tumor Center. Dr. Nair has 30 years of experience in the field of immunology and has gained
national and international reputation as a leader in the field of T cell immunity, specifically the induction of T cell responses by dendritic cells. She started her research career in viral immunology and then transitioned to
cancer immunology and immune-based therapies. Dr. Nair’s team develops novel immune-based therapies against cancer and conducts bench-to-bedside translational studies. She is a key inventor of the landmark invention: the
use of tumor antigen RNA transfected dendritic cells as vaccines. Dr. Nair is also investigating oncolytic poliovirus immunotherapy and is examining oncolytic poliovirus-mediated immune changes in the tumor microenvironment (in
mice and patients with cancer. Another focus of Dr. Nair’s laboratory is to augment the clinical benefit associated with immunotherapy. This includes developing combination therapies designed to induce immune responses and
block immune suppression.
|Dhaval Nanavati, PhD||AbbVie|
Dhaval Nanavati completed his PhD at University of Connecticut
and Post doctoral fellow ship at Laboratory of Neurotoxicology, National Institute of Mental Health. In 2009, he joined Northwester to start new proteomics core and was director till 2016. He joined AbbVie in 2016 as Sr. Scientist,
|Brent Nannenga, PhD||Arizona State University|
Assistant Professor, Chemical Engineering
Brent Nannenga is an Assistant
Professor of Chemical Engineering in the School for Engineering of Matter, Transport and Energy at Arizona State University. He is also a member of the Biodesign Institute’s Center for Applied Structural Discovery. Research
the Nannenga lab focuses on using structural biology, specifically crystallography and cryo-EM, to understand and engineer improved biomolecular systems, and to use engineering principles to develop novel methods in structural
biology in order to solve high-resolution structures of difficult, yet extremely important targets.
|Horacio G. Nastri, PhD||Incyte Corporation |
Senior Director, Antibody Biotherapeutics
No bio available
|Brad Nelson, PhD ||British Columbia Agency|
Co-Director, Immunotherapy Program
Dr. Nelson is a native of Vancouver, Canada.
He received his B.Sc. from the University of British Columbia in 1987 and Ph.D. from the University of California at Berkeley in 1991. He completed postdoctoral training with Dr. Phil Greenberg and held faculty positions at the
Fred Hutchinson Cancer Research Center and University of Washington in Seattle. In 2003, he became the founding Director of BC Cancer's Deeley Research Centre in Victoria BC. He is a Professor of Medical Genetics at the University
of British Columbia. Dr. Nelson’s lab uses genomic and molecular approaches to study the immune response to cancer, with an emphasis on ovarian cancer. As Co-director of BC Cancer’s Immunotherapy Program, he is leading
a phase I clinical trials program focused on adoptive T cell therapy for gynecological cancers, leukemia, lymphoma, and other malignancies.
|Jennifer F. Nemeth, PhD, SCPM||Janssen Research & Development|
Director, Biophysics, Structural Characterization, Biologics Discovery Sciences
Dr. Nemeth obtained a B.S. in Chemistry from the University of Scranton in 1995 followed by a Ph.D. in Analytical Chemistry from Emory University in 1999. After graduation, she worked under Dr. Richard Caprioli at Vanderbilt
University as a post-doctoral research follow focusing on applied bioanalytical mass spectrometry. Leaving academia in 2000, Dr. Nemeth entered the biopharmaceutical industry where she was employed as a bioanalytical mass spectrometrist
at Genetics Institute (now Wyeth BioPharma) and ExSAR Corp. Dr. Nemeth joined Centocor (Now Janssen) in 2004 to head a new mass spectrometry group focused on the characterization of molecules from inception through pre-clinical.
In 2012, Dr. Nemeth stepped outside the Biophysics area to oversee discovery and clinical drug programs. In July 2017, Dr. Nemeth returned to Biophysics to create a new structural characterization lab focused on structural analyses
to drive discovery programs. Her publications include detailed protein characterizations, as well as new methods for protein analysis using mass spectrometry.
|Dario Neri, PhD||Swiss Federal Institute of Technology (ETH Zurich)|
Professor, Chemistry & Applied Biosciences
Dario Neri was born in Rome
on 1 May 1963, but grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor
Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral research internship (1992-1996) at the Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter, he became professor at
ETH Zürich in 1996. Dario Neri is currently Full Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, ETH Zürich. The research of the Neri group focuses on the engineering of therapeutic
antibodies for the therapy of cancer and other angiogenesis-related disorders. Other research activities include the chemical proteomic discovery of novel vascular markers of pathology and the development of DNA-encoded chemical
libraries. Dario Neri is a co-founder of Philogen (www.philogen.com), a Swiss-Italian biotech company which has brought various antibody products into multicenter clinical trials for the treatment of cancer and of chronic inflammatory
conditions. Dario Neri has published over 350 articles in peer-reviewed scientific journals. He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, of the Mangia d’Oro 2001, of the
Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer of the French Medicinal Chemistry Society in 2011,
of the Phoenix Prize 2014 and of an ERC Advanced Grant in 2015.
|Anton Neschadim, PhD, MBA||ImmunoBiochem Corporation|
Anton is a biomedical professional, scientist, innovator, entrepreneur
and venture capitalist with more than 15 years of industry and academic experience in research and drug development. At ImmunoBiochem Corporation, Anton is leading the development of a new class of tumor microenvironment-targeted
anti-cancer therapeutics. Anton was formerly the Director of Drug Development at Armour Therapeutics Inc., a biopharmaceutical company developing a new class of anti-cancer therapeutics for prostate, breast and ovarian cancers.
Throughout his career, Anton worked on R&D and consulting projects with several biopharmaceutical companies developing biological therapeutics and immunotherapies in oncology. Anton has expertise in cancer research, immunology,
chemistry, regenerative medicine and gene therapy, and authored more than 25 peer-reviewed publications and patents. Anton obtained his PhD, MSc, and Hon. BSc degrees in medical biophysics, immunology, and biological chemistry
at the University of Toronto, where he also completed postdoctoral work and his MBA at the Rotman School of Management. Anton was also a trainee of the CIHR Training Program in Regenerative Medicine (TPRM), Toronto General Hospital,
University Health Network. Anton was a founding board member, and former CCO and organizing committee member of the Canadian Science Policy Centre (Toronto, ON) – a national organization promoting science policy in Canada.
Anton has led several venture capital investments in biomedical and healthcare companies at GreenSky Capital.
|Chris Neumann, PhD||Seattle Genetics |
Principal Scientist, Medicinal Chemistry
Chris Neumann, PhD, is a Principal
Scientist in the Medicinal Chemistry group at Seattle Genetics. He completed his graduate studies in chemistry at Harvard University in 2006, and subsequently pursued postdoctoral research at Harvard Medical School in the Department
of Biological Chemistry and Molecular Pharmacology. Following a period of independent research at the University of Washington, he joined Seattle Genetics in 2012 where his research program focuses on the development of novel payloads
for antibody-drug conjugates and new linker technologies to better enable targeted delivery of drugs.
|Ahuva Nissim, PhD||Queen Mary University|
Professor, Antibody and Therapeutic Engineering, Biochemical Pharmacology
Nissim graduated in Molecular Immunology in Weizmann Institute of Science in Israel and was trained as a postdoctoral fellow at the MRC Centre for Protein Engineering in Cambridge until 1995. During this period, she developed a
phage display semi-synthetic human antibody library which has been used worldwide. She joined Queen Mary University in 2000.
|Tatiana Novobrantseva, PhD||Verseau Therapeutics|
Co-Founder, Head of Research and Development
Dr. Tatiana Novobrantseva
is a co-founder and the Head of Research and Development in the new immunology focused company Verseau Therapeutics. Prior to co-founding Verseau, she consulted for multiple companies on various immunological aspects of drug development
across different stages and therapeutic modalities. At her prior position as Director of Tumor Immunology at Jounce Therapeutics, Tatiana defined research plans for several programs at the company’s inception, as well as
led a portfolio of programs on (re)activating the immune system against cancer. Her previous positions include Associate Director at Alnylam Pharmaceuticals and Scientist II at Biogen. Some of Tatiana’s scientific accomplishments
include discovering the critical role for B cells in liver fibrosis, pushing the envelope on siRNA delivery to immune cells and championing a siRNA-assisted dendritic cell cancer vaccine project. Tatiana is an inventor on more
than 22 patents and an author on more than 36 peer-reviewed manuscripts. Tatiana completed her PhD with Dr. Klaus Rajewsky in Cologne, Germany, focusing on B cell development and function.
|Mark O’Hara, MD||University of Pennsylvania|
GI Malignancy Oncologist
No bio available
|Maureen O'Connor-McCourt, PhD||Forbius|
Maureen is a prolific inventor and an expert in the development
of targeted biological therapeutics. She has published over 100 peer-reviewed manuscripts, including over 50 publications in the TGF-β field. Maureen also holds numerous patents. Prior to joining Forbius, Maureen was Principal
Research Officer and Section Leader at the Canadian National Research Council (NRC). While at NRC, Maureen served as a Scientific Leader of NRC's Biologics Program, a pan-Canadian network of over 10 research teams. Under her leadership,
this program established a successful track record in developing innovative protein therapeutics, many of which are under active clinical investigation. Maureen is the recipient of many awards, including the Gervais-Dionne Award
(2012) for her work on “New Cancer Targets and Matching Antibodies for Diagnostic and Therapeutic Use”. Maureen received her Ph.D. in Biochemistry from the University of Alberta and completed post-doctoral training
at the laboratory of Drs. Michael Sporn and Anita Roberts, where TGF-β proteins and their relation to carcinogenesis was newly-discovered.
|Martin Oft , PhD ||ArmoBio|
Senior Vice President, Preclinical and Clinical R&D,
No bio available
|Eliud Oloo, PhD||Schrödinger|
Senior Principal Scientist
Eliud Oloo is a Senior Principal Scientist at Schrödinger
where he works on computational design and optimization of Biologics. Prior to joining Schrödinger, he was a research scientist at Sanofi for over ten years, spearheading structure-based vaccine design initiatives against
a variety of infectious disease targets. Eliud completed his Ph. D. in Biomolecular Simulations at the Department of Biological Sciences, University of Calgary, Canada.
|Shimobi Onuoha , PhD ||Autolus |
Head, Protein Engineering
No bio available
|Ira H. Pastan, MD||NIH|
Co-Chief, Laboratory of Molecular Biology; NIH Distinguished Investigator; Head, Molecular Biology Section
Ira Pastan is co-chief of the Laboratory of Molecular Biology, National Cancer Institute. He is interested in targeted cancer therapy with Recombinant Immunotoxins. These are chimeric proteins in which the Fv of a Mab reacting
with a cancer cell is fused to a portion of Pseudomonas exotoxin A. His group is conducting clinical trials with SS1P and LMB-100 that target mesothelin and has completed a Phase III trial with Moxetumomab pasudotox that targets
CD22 in Hairy Cell Leukemia. His current research is directed at improving the properties of these agents and combining them with check point inhibitors.
|Belinda Pastrana||Protein Dynamic Solutions|
Chief Executive Officer
Following her training at Rutgers and Mayo, Dr. Pastrana has dedicated
thirty years to developing and patenting cutting-edge solutions for protein and biologic characterization. She is a tenured faculty member at the University of Puerto Rico, and has trained a generation of students for subsequent
employment in the biopharmaceutical industry.
|Li Peng, PhD,||Palleon Pharmaceuticals|
Vice President, Biotherapeutics Discovery
Li Peng is a Vice President of Biotherapeutics
Discovery at Palleon Pharmaceuticals, a leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. Li led the invention of two core platform technologies for Palleon – the EAGLE
platform for targeting glyco-immune checkpoint ligands, as well as the HYDRA platform for enabling patient stratification. Previously, she worked at Medimmune/AstraZeneca for ~10 years with increasing responsibilities from antibody
engineering and characterization to leading drug discovery programs and cross-functional project teams. Li has a PhD in Biochemistry, MS in Genetics, and BS in Biology. She has published ~30 papers and authored 7 patents.
|Thomas Pillow, PhD||Genentech, Inc.|
Senior Scientist, Discovery Chemistry
Thomas Pillow received his Ph.D from
Stanford University in organic chemistry under the direction of Professor Paul Wender. Upon graduation he moved to Genentech in 2009 where he is currently a senior scientist in the discovery chemistry department leading Genentech’s
effort on antibody-drug conjugates.
|Guy Poirier, PhD||Université Laval|
Professor, Faculty of Medicine, Scientific Advisor, Proteomics Platform CHU of Quebec
Guy G. Poirier, a professor at the Université Laval, is one of the world leaders in the field of proteomics, and he is undoubtedly the foremost specialist in the study of certain enzymes (PARP) that play a fundamental
role in signalling DNA damage and in its repair. A better understanding of DNA damage signals and of a phenomenon known as apoptosis (programmed cell death) will greatly improve the diagnosis and treatment of widespread diseases
such as cardiovascular disease, diabetes, neurodegenerative diseases and several types of cancer. An extremely prolific author, Dr. Poirier is the most cited researcher in this field.
|Tony Polverino, PhD||Zymeworks Inc.|
Executive Vice President of Early Development & CSO
PhD, joined Zymeworks in September 2018 and currently serves as Executive Vice President of Early Development and Chief Scientific Officer. Prior to joining Zymeworks, from 2015 until 2018, Dr. Polverino was at Kite Pharma, Inc.,
which was acquired by Gilead Sciences, Inc. in 2017. While at Kite he served as the interim Chief Scientific Officer and before that as Vice President of Research. During his tenure, Yescarta®, Kite's lead chimeric antigen
receptor (CAR)-T cell therapy, was approved for relapsed or refractory B cell lymphoma, and multiple programs were advanced to the clinic. Dr. Polverino also assembled an innovative chimeric antigen receptor discovery and development
team. Prior to Kite, he was at Amgen Inc. from 1994 to 2014, serving in a number of research leadership roles of increasing responsibility. While at Amgen he managed and advanced numerous research programs utilizing multiple therapeutic
modalities, including immunotherapy, oncolytic viruses, bispecific antibodies, antibody-drug conjugates, and small molecules. He also played a key role in the development of over 12 novel antigens for antibody therapeutics. Dr.
Polverino earned his undergraduate degree in pharmacology from Adelaide University and his Ph.D. in biochemistry from Flinders University, both in Adelaide, Australia.
Director, Analytical Development
Francis Poulin is a Director of Analytical
Development at Sanofi in Framingham, Massachusetts, where he is responsible for the development, qualification and validation of bioassays and molecular assays to support the release of biologics in preclinical and clinical development,
including gene therapy products. Prior to joining Sanofi, Francis was a postdoctoral fellow at HHMI/University of California, Berkeley and the Lawrence Berkeley National Laboratory. Francis received his PhD in Biochemistry from
|Daniel Powell, PhD ||Penn|
Associate Professor of Pathology and Laboratory Medicine
The Powell Lab
is actively investigating the application of immune-based therapy for cancer. Building on interrogations in basic T cell biology in the lab, bench-to-bedside translational immunology is being developed, with a strong focus on T
cell-based therapy for ovarian cancer.
|Ken Prentice||Shape Therapeutics|
Associate Director, Manufacturing Technologies
Ken Prentice graduated from
the University of Washington with BS degrees in both Chemistry and Oceanography. He pursued a brief career as a Forensic Scientist with the Washington State Patrol before joining Amgen in 2002. Ken spent the next 13 years across
Quality and Analytical Development organizations at Amgen with the final 5 years focusing on high resolution chromatography and mass spectrometry for in depth characterization of monoclonal antibodies. Ken joined Juno Therapeutics
in 2015 with the goal of introducing bioanalytical and physiochemical techniques and built a high performing team of biochemists who developed of the state of art and innovative methods to support process development and characterization
of cell therapy products. Most recently Ken joined Shape Therapeutics to help bring novel gene therapies to market.
|Nuša Pristovšek, PhD||Technical University of Denmark|
Postdoctoral Researcher, The Novo Nordisk Foundation Center for Biosustainability (CFB)
Nuša Pristovšek is a postdoctoral researcher at The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark. Her current research is focused on the development of high-throughput screening
and genome-editing technologies for optimization of CHO cell factories with industrial applications. In particular, she is interested in improving targeted integration approaches allowing for programmable mammalian engineering
and controllable recombinant protein production.
|John Proctor||Halo Labs|
Vice President, Marketing
John did his doctoral
work in Neuroscience at UCSF where he made several transgenic mice studying the role of beta8 integrin in neurovascular development. After graduating, he entered the life science tools space working for organizations that have
consistently challenged the status quo in bioanalytical and cell analysis instrumentation. John recently joined Halo Labs as VP of Marketing.
|Ronald T. Raines, PhD||Massachusetts Institute of Technology |
Firmenich Professor of Chemistry, Department of Chemistry
Ron Raines is
the Firmenich Professor of Chemistry at the Massachusetts Institute of Technology and an Associate Member of the Broad Institute of MIT and Harvard. He received ScB degrees in chemistry and biology from MIT, performing undergraduate
research with Christopher T. Walsh. He received AM and PhD degrees in chemistry from Harvard University for research done with Jeremy R. Knowles. He was a Helen Hay Whitney postdoctoral fellow with William J. Rutter in the Department
of Biochemistry and Biophysics at the University of California, San Francisco. He joined the faculty at the University of Wisconsin–Madison in 1989, was a Visiting Associate at Caltech in 2009, and returned to MIT in 2017.
Raines has contributed broadly to our understanding of the chemistry and biology of proteins. He discovered an RNA-cleaving enzyme that is in a multi-site human clinical trial as an anti-cancer agent; revealed that unappreciated
forces—the n→π* interaction and C5 hydrogen bond—stabilize all proteins; created hyperstable and human-scale synthetic collagens; and developed processes to synthesize proteins, catalyze their folding, and facilitate
their entry into human cells, and to convert crude biomass into useful fuels and chemicals. Dr. Raines has published over 500 papers and abstracts, delivered over 300 invited lectures, and supervised 58 doctoral theses. He holds
57 U.S. patents, and founded Quintessence Biosciences, Inc.; Hyrax Energy, Inc.; and Ghost Proteins, Inc., which are developing inventions from his laboratory.
|G. Jonah Rainey, PhD||Oriole Biotech, Inc.|
Jonah Rainey holds a PhD in Biochemistry from Tufts University and completed
postdoctoral training at the University of Wisconsin and the Salk Institute. He has been actively engaged in discovery, research, and development of bispecific antibodies in a biotech setting for 12 years. He is an inventor on
several patents and applications describing novel bispecific platforms as well as current clinical candidates that exploit these platforms. Dr. Rainey led or had major contributions to research and early development of at least
three current clinical candidates in Phase I and II, and led many additional advanced preclinical programs in oncology, infectious disease, autoimmunity, and other therapeutic areas. Industry experience spans small biotech (MacroGenics,
MabVax) and large pharma settings (MedImmune/Astrazeneca).
|Romesh Rao||Seattle Genetics|
Research Associate, Analytical Sciences
Romesh has over six years of experience
in biopharmaceutical analytical development and has an in-depth knowledge of mass spectrometry techniques and protein characterization. He joined Seattle Genetics as a member of the Analytical Sciences Mass Spectrometry Core Group
in 2015. In his current role he is responsible for providing analytical characterization to support process development for early and late phase antibody-drug conjugate programs. Romesh earned his B.Sc degree in Neurobiology from
the University of Washington.
|Harun Rashid, PhD||Ambrx|
Senior Principal Scientist, Molecular Technology
Harun has 18 years of biotech
R&D experience in cutting-edge molecular biology with expertise in protein engineering and recombinant protein expression optimization, synthetic biology, genome engineering and strain development. Currently, as Head of Molecular
Technology Department and Project leader for anti-CD3 bispecific program at Ambrx, Harun is leading the efforts to identify and optimize antibodies for multiple immuno-oncology programs. Prior to that, he had engineered protein
therapeutics, and optimized expression systems at Genencor International and at Catalyst Biosciences from which three molecules are now in various stages of clinical development in hemophilia and oncology areas.
|Harun Rashid, PhD||Ambrx, Inc.|
Senior Principal Scientist, Molecular Technology
Harun has 18 years of biotech
R&D experience in cutting-edge molecular biology with expertise in recombinant protein expression and engineering, synthetic biology, genome engineering and strain development. Currently, Harun is leading the Molecular Technology
Department at Ambrx, Inc. to optimize their NNAA incorporation technology for the production of protein therapeutics in bacterial (ReCODE) system. Prior to that, he had engineered protein therapeutics, and optimized expression
systems for development candidates at Genencor International and at Catalyst Biosciences that had moved to clinical stages.
|Andreas Raue, PhD ||Merrimack|
Associate Director, Research,
Andreas Raue develops new therapeutic strategies
for cancer treatment by combining in vivo and in vitro experimentation with systems and computational biology approaches. Currently, he is Associate Director of Research at Merrimack Pharmaceuticals, where he leads the preclinical
|Jeffrey V. Ravetch, MD, PhD||Rockefeller University|
Theresa and Eugene M. Lang Professor, Immunology, Virology, and Microbiology
No bio available
|Sai Reddy, PhD||ETH Zurich|
Assistant Professor, Biosystems Science and Engineering
Sai Reddy is an Associate
Professor in the Department of Biosystems Science & Engineering, ETH Zurich, Switzerland. His research group uses methods in systems and synthetic biology to study and manipulate immune responses for applications in biotechnology,
vaccination, and immunotherapy. Sai Reddy holds B.S. (2003) and M.S. (2004) in Biomedical Engineering from Northwestern University (Evanston, IL, USA). He completed his Ph.D. thesis at Ecolé Polytechnique Féderale
de Lausanne (EPFL, Switzerland) in Bioengineering and Biotechnology (2008). Sai Reddy did post-doctoral research at the University of Texas, Austin (2008-2011).
|Will Redmond, PhD ||Providence|
Associate Member, Laboratory of Cancer Immunotherapy, Director, Immune Monitoring Laboratory,
The overall goal of our research is to elucidate the mechanisms by which the provision of co-stimulatory signals in conjunction with checkpoint inhibitor blockade boosts tumor immunotherapy. Specifically, we are interested in
how these therapies augment the function and differentiation of tumor-specific T cells. Another major focus of my laboratory is investigating the mechanisms by which vaccination plus combination immunotherapy rescues anergic CD8
T cells to augment anti-tumor immunity. In addition, we are investigating how tumors suppress T cell-mediated immunity and are developing novel approaches to overcome this hurdle to generate more potent anti-tumor immunity.
|Pillutla Renuka, PhD||BMS|
Executive Director, Lead, Bioanalytical Sciences
She leads the Bioanalytical
Sciences Department comprising bioanalytical discovery, development andbiomarker functions that support small and large molecules and novel modalities at BMS.
|Paul M. Ridker, MD, MPH||Harvard Medical School|
Eugene Braunwald Professor of Medicine
Dr. Ridker serves as the Eugene Braunwald
Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston focused on inflammatory mechanisms
of atherosclerosis, population biology, genetic epidemiology, and the biology of innate immunity and vascular inflammation as it relates to cardiovascular disease and atherosclerosis. Among ongoing multi-national projects, Dr.
Ridker currently serves as Trial Chairman of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) and the NIH-sponsored Cardiovascular Inflammation Reduction Trial (CIRT), large-scale outcome trials seeking to address
whether reducing inflammation without altering LDL cholesterol can reduce vascular event rates.
|Frank J. Riske, PhD||BioProcess Technology Consultants, Inc.|
Frank J Riske, Ph.D., Senior Consultant at BioProcess
Technology Consultants has over 25 years of experience in the biopharmaceutical industry. Prior to joining BioProcess Technology Consultants, Dr. Riske was Senior Director in the Late Phase Process Development Group at Genzyme,
a Sanofi company. Before Genzyme, Dr. Riske held positions at Epic Therapeutics, Repligen and Hoffmann-LaRoche. Dr. Riske has extensive experience in the development of downstream processes for cytokines, proteins and virus from
plasma, E coli, Pichia and mammalian systems and in the development and manufacture of novel drug delivery systems. Dr. Riske received his B.S. in Biology from Fairfield University, Ph.D. in Biochemistry and Microbiology from Rutgers
University and completed a post-doctoral position at Hoffmann-LaRoche.
|Mark Rixon, PhD||Alpine Immune Services|
Senior Director, Protein Therapeutics
Mark Rixon has over 30 years of industrial
experience focusing on recombinant protein expression, antibody generation, and protein engineering resulting in contributions to the development of therapeutic protein candidates currently in Phase II and Phase III clinical trials
and pre-clinical development, including recombinant monoclonal antibodies, receptor-Fc fusion proteins, and bispecific antibodies. Presently, Mark is Senior Director of Protein Therapeutics at Alpine Immune Sciences, a biotechnology
company developing IgSF receptor-Fc fusion proteins as biotherapeutics in autoimmune/inflammation and immuno-oncology applications.
|Kernstock Robert, PhD||PPDI|
Senior Group Leader, R&D, Immunochemistry
Scientist with expertise in the following therapeutica
areas: inflammation/immunology, oncology, & CNS. Direct assay development, validation, and sample analysis from clinical trials under GLP conditions for the assessment of pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity,
genomics (PGx), and Companion Diagnostics (CDx). Project management of out-sourced development partners (CROs) and budgets.
|Marc-André Robert, PhD||BioMarin Pharmaceuticals|
Scientist, Technology Development
Marc-André Robert is passionate
by the development of novel applications and manufacturing technologies for recombinant adeno-associated, lentiviral and adenoviral vectors. From 2008 to 2013, he did his Ph.D. off-campus at the National Research Council Canada
(NRC) and obtained his degree from the University of Montreal. His work aimed at developing a gene therapy approach for Duchenne muscular dystrophy using gutless adenoviral vectors and gene editing. After his Ph.D., he started
a postdoctoral fellowship at the NRC and Laval University where he developed a new platform for production of HIV-1 virus-like particles as a mean to deliver therapeutic proteins. In addition, he explored a new preventive immunotherapy
approach for Ebola infections using adeno-associated vectors and achieved up to 100% protection in mice. BioMarin Pharmaceutical Inc. - an innovative company specialized in the treatment of rare inherited diseases - hired him in
2017 as a scientist and gene therapy expert. He is currently developing new platforms/processes for production of lentiviral and adeno-associated vectors.
|David D. Roberts, PhD||NCI, NIH|
Senior Investigator, Head, Biochemical Pathology Section, Laboratory of Pathology, CCR
Dr. Roberts received his BS in Chemistry from the Massachusetts Institute of Technology and his PhD in Biological Chemistry from The University of Michigan. He is currently a Senior Investigator and Head of the Biochemical Pathology
Section in the Laboratory of Pathology of the National Cancer Institute. He is an elected Fellow of the American Association for the Advancement of Science and recipient of a NCI Director's Merit Award and several NIH Federal Technology
Transfer Awards. His research focuses on the tumor microenvironment and the role of cell-extracellular matrix interactions in regulating tumor angiogenesis and antitumor immunity. His laboratory discovered molecular mechanisms
by which thrombospondin-1 signaling through its receptor CD47 regulates redox signaling in vascular cells, the activation and cytotoxic function of T lymphocytes, and the maintenance of malignant and nonmalignant stem cells. His
lab is developing therapeutics to target CD47 that protect nonmalignant tissues from cytotoxic stress while enhancing adaptive antitumor immunity.
|Gabriel Rocklin, PhD||Northwestern University|
Assistant Professor, Department of Pharmacology & Center for Synthetic Biology
Rocklin did his Ph.D. research at the University of California, San Francisco, supervised by Brian Shoichet and Ken Dill. There, he developed methods to improve the accuracy of molecular dynamics-based free energy calculations
of protein-ligand binding. He then joined David Baker's lab at the University of Washington as a postdoctoral fellow, where he pioneered the use of large-scale protein design to understand protein biophysics. This work makes it
possible to computationally design and experimentally characterize thousands of diverse proteins for folding, binding, dynamics, and therapeutic potential. In March 2019 he is opening his independent lab in the Pharmacology Department
of Northwestern University as part of Northwestern's Center for Synthetic Biology.
|Theo Roth, PhD ||UCLA|
Department of Microbiology and Immunology,
Theo Roth is an MD/PhD student at
the University of California, San Francisco working with Dr. Alexander Marson. He completed his undergraduate studies in Biology and a masters in Biomedical Informatics at Stanford University. While an undergrad he studied the
immediate cellular response to traumatic brain injuries at the National Institutes of Health with Dr. Dorian McGavern. At UCSF he has developed non-viral gene editing tools in human T cells for rapidly accelerated cancer and autoimmune
cell therapies applications.
|Gargi Roy, MSc||MedImmune, LLC|
Scientist, Antibody Discovery and Protein Engineering
Gargi Roy is a Scientist
in MedImmune, LLC. She has been involved with protein expression technology development, cell line engineering and antibody expression for more than 15 years. Prior to MedImmune, she had held various positions within Acorda Therapeutics
Inc., US Patent Office and academic institutions such as Georgetown University in Washington DC and UTMB at Galveston, TX.
|Marco Ruella, PhD ||Penn|
Clinical Instructor, Associate Director, Dr. June’s Laboratory, Center for Cellular Immunotherapies, Perelman School of Medicine
Dr. Marco Ruella obtained his medical degree with high honors at the University of Torino, Italy, in 2007, and completed his specialization in clinical hematology in 2012. He worked as attending physician at the Hematology and
Cell Therapy Division of the Mauriziano Hospital and was Instructor at the Biotechnology School at the University of Torino. From 2012 to 2018 he was a Post-doctoral fellow and then Instructor at the University of Pennsylvania
in the Center for Cellular immunotherapies under the mentorship of Drs. Carl June and Saar Gill. From 2017 to 2018 Dr. Ruella served as the Associate Director of Dr. June’s laboratory. In 2018 Dr. Ruella was appointed Tenure-track
Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the University of Pennsylvania. His research is focused on the
mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma. Dr. Ruella was awarded the
inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese”
Award Leukemia Research (2017) and more recently the Cancer Support Community Award (2018). Dr. Ruella is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor
in several patents on CART therapy.
|Brandon Ruotolo, PhD||University of Michigan|
Brandon T. Ruotolo received his B.S. degree in Chemistry
from St. Louis University in 1999. While there, he was able to participate in some undergraduate research under the direction of Dana M. Spence (currently at Michigan State, Department of Chemistry). He then went on to join David
H. Russell’s research group at Texas A&M. While at A&M, Brandon focused on the design, development, and implementation of hybrid Ion Mobility-Mass Spectrometry (IM-MS) instrumentation for applications in proteomics,
and received his Ph. D. in 2004. Directly after his graduate work, Brandon joined Prof. Dame Carol Robinson’s laboratory at the University of Cambridge in the United Kingdom, and pioneered the construction of IM-MS methods
for the analysis of multi-protein complex structure. In 2009, Brandon began his independent career the Department of Chemistry, at the University of Michigan, where he currently holds the rank of Professor of Chemistry. The Ruotolo
group is primarily focused on developing IM-MS as a next-generation high-throughput tool for structural proteomics and drug discovery. As of 2018, Brandon’s record currently includes over 107 peer reviewed publications, as
well as ~150 invited or keynote seminars at institutions and conferences around the world. Brandon’s work as an independent investigator has garnered a number of awards, including the Eli Lilly Young Investigator award, an
NSF CAREER award, the American Society for Mass Spectrometry Research Award, the Ralph E. Powe Junior Faculty Enhancement Award, the Protein Society Young Investigator Award, and the Agilent Thought Leader Award.
|Charlotte Russell, MD, PhD||Alligator Bioscience AB|
Charlotte A. Russell is a medical doctor with board certifications
in hematology and internal medicine and has a PhD from Copenhagen University. Charlotte has more than 25 years of research and clinical experience, including more than 10 years with clinical drug development in biotech/pharmaceutical
companies. The drug development experiences are focused on development of antibodies for cancer therapy.
|Stephen J. Russell, MD, PhD||Vyriad Inc.|
Dr. Russell is the CEO of Vyriad. He is also the Richard O Jacobson
Professor of Molecular Medicine at Mayo Clinic and Vice President of the American Society of Gene and Cell Therapy. He obtained his MD from the University of Edinburgh in 1982 and since that time has relentlessly pursued the goal
of effective oncolytic virotherapy. He specialized clinically in hematology, then undertook his PhD training at the Royal Marsden hospital where he was the first to engineer both retroviral and parvoviral vectors to deliver interleukin
genes for cancer immunotherapy. He then moved to Cambridge, England where he led a research team in the MRC Laboratory for Molecular Biology, developed a novel method for antibody affinity maturation using phage display libraries,
pioneered the display antibody domains on retroviral vector particles and on recombinant measles viruses, and founded Cambridge Genetics, a biotechnology/drug discovery company. In 1998 he moved to Mayo Clinic where he founded
the Department of Molecular Medicine, built a comprehensive oncolytic virotherapy program, developed innovative engineering approaches for targeting, arming and noninvasively monitoring OV infections, and orchestrated the GMP manufacture,
preclinical pharmacological/toxicological testing, IND filing and clinical translation of a number of oncolytic Measles and Vesicular stomatitis viruses for several different cancer indications. He cofounded two oncolytic virotherapy
companies which merged in 2015, thereby establishing Vyriad as the first multi-platform OV company.
|Clifford William Sachs, PhD||MedImmune|
Director, Research and Development, Toxicology
Clifford Sachs has over
15 years of experience developing biological drugs including antibodies, fusion proteins, cell and gene therapies. Before joining MedImmune, Clifford was a Scientific Director and Janssen Fellow at Johnson and Johnson and previously
held positions of increasing responsibility in toxicology groups at Biogen Idec, Abbott and Novartis Pharmaceuticals. He served as a member of the Biotechnology Organization (BIO) BioSafe Leadership committee and Chaired the BioSafe
Cell Therapy and Specialty Biologics Expert Working Groups (SBEWG). Clifford is certified by the American Board of Toxicology, earned his PhD in Pathology from Duke University and BSin Biology and Chemistry from Muhlenberg College.
In addition to his vocation, Clifford has an avocation: he is a part-time ski instructor. He holds a Level 1 certification from the Professional Ski Instructors Association of America and has taught over 1100 people how to ski.
|Jochen Salfeld, PhD||AbbVie|
Vice President, Global Biologics; Distinguished Research Fellow
Doctorate in Microbiology and Molecular Biology from the University of Heidelberg, Germany • Postdoc at Center for Molecular Biology Heidelberg, Germany, Yang Ming Medical College, Taipei, Taiwan and Dana Farber Cancer Institute,
Boston, MA, USA • Scientist in roles of increasing responsibility at BASF Bioresearch Corporation, which is today AbbVie Bioresearch Center in Worcester MA
|Markku Saloheimo, PhD||VTT Technical Research Centre of Finland, Ltd.|
Senior Principal Scientist, Industrial Biotechnology and Food Solutions
I have over 25 years of experience in developing production systems for industrial enzymes and therapeutic proteins. My work has mostly focused on filamentous fungal hosts, where I have work on the molecular mechanisms of gene
regulation and protein secretion as well as the creation of novel fungal strains with higher productivity.
|Lobelia Samavati, MD||Wayne State University School of Medicine |
Associate Professor of Medicine, Department of Medicine, Center for Molecular Medicine and Genetics
Dr. Samavati is a tenured Associate Professor of Medicine and Molecular Medicine and Genetics, Department of Medicine, Division of Pulmonary Critical and Sleep Medicine and Center for Molecular Medicine and Genetics.
|Garces Sandra, MD, PhD||Lilly|
Senior Medical Advisor for Immunogenicity, GPS Medical and Benefit-Risk Management
Sandra Garces, MD PhD, works at Eli Lilly since 2016, as Senior Medical Advisor in Global Patient Safety, focused on IMG-related aspects. Previously she worked as Rheumatologist-Scientist at Garcia de Orta’s Hospital and
Gulbenkian Institute of Science, in Lisbon. Her work has been focused on revealing the clinical relevance of drug immunogenicity and developing strategies to assess and incorporate immunogenicity information in routine clinical
practice towards more cost-effective therapeutic strategies.
Senior Director Business Development
No bio available
|Barbra Sasu, PhD ||Allogene|
Barbra Sasu is the Chief Scientific Officer (CSO) of Allogene Therapeutics,
a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Barbra
joined Allogene as CSO in April 2018 when the company acquired the allogeneic cell therapy assets from Pfizer. Barbra received her Ph.D. from the Paterson Institute for Cancer Research in Manchester, UK in the laboratory of T.
Michael Dexter, FRS. She conducted her postdoctoral research at Harvard Medical School in the laboratory of T. Keith Blackwell, M.D., Ph.D. Barbra joined Amgen in 2001 to work on normal and malignant hematology initially and later
expanded her focus to include immuno-oncology (IO) with a large emphasis on T cell redirective therapies, specifically BiTE molecules. In 2013 she joined Pfizer to become involved with large molecule IO including the Pfizer T cell
redirection programs and led diligence to look for a CAR T collaboration partner. This collaboration search resulted in the Cellectis partnership in 2014 and the collaboration with Servier, for clinical execution of UCART19 and
for other preclinical assets.
|Aaron Sato||Twist Bioscience|
Chief Scientific Officer
Aaron is CSO of the Pharma Vertical at Twist Bioscience.
Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw all discovery research functions both as
Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma, Inc. He also held director level positions at both Oncomed and Dyax Corp.
|Andreas Schaaf, PhD||Greenovation Biotech GmbH|
Chief Scientific Officer
Andreas holds a PhD in plant biotechnology. Before
joining Greenovation in 2009, he held positions at Universities of Muenster and Freiburg. At Greenovation, Andreas was responsible for advancing BryoTechnology to a fully viable biopharmaceutical platform and establishing the company’s
product pipeline. Since 2015, Andreas is acting as Chief Scientific Officer. Dr. Sharfstein joined the faculty at the University of Toledo in Bioengineering in 1996. In 2000, she received a National Science Foundation POWRE award
to study glycobiology at the New York State Department of Health Wadsworth Laboratories. In 2001, she joined the Department of Chemical and Biological Engineering at Rensselaer Polytechnic Institute, and in 2007, she received a
dual appointment in Biology. In 2010, she joined the faculty at SUNY Polytechnic Institute, Colleges of Nanoscale Science and Engineering.
|Jonas V. Schaefer, PhD||Novartis Institutes for BioMedical Research (NIBR)|
Lab Head/Investigator II
Dr. Schaefer is heading an R&D laboratory
supporting Novartis’ lead finding through the utilization of Encoded Library Technologies (e.g. DNA encoded libraries (DEL)), using various screening methods to select low-molecular-weight compounds against a broad variety
of protein targets. Prior to this assignment, Jonas did establish and headed the High-Throughput Binder Selection Facility at the University of Zurich for many years, using automated Ribosome Display and various High-Throughput
screenings to develop specific proteinaceous affinity reagents called DARPins. For over a decade, Jonas focused on the development of new methodologies and technologies enabling the improved generation, screening and validation
of various affinity compounds, which were used in applications ranging from basic research to diagnostic usage and medical applications.
|Volker Schellenberger, PhD||Amunix Pharmaceuticals, Inc.|
President and Chief Technology Officer, Research & Discovery
Volker Schellenberger is a co-founder of Amunix and currently serves as President and Chief Technology Officer. Dr. Schellenberger has extensive industry experience in protein engineering and drug discovery. Previously, he headed
the Protein Engineering department at Genencor, where he invented combinatorial consensus mutagenesis, selection by micro-compartmentalization, as well as mutator technology. In addition, he initiated and led collaborations with
Seattle Genetics that focused on antibody-enzyme fusion proteins. Prior to his work on biotherapeutics, Dr. Schellenberger directed projects optimizing enzymes for industrial applications as well as microbes for metabolic pathway
engineering. Dr. Schellenberger received his Ph.D. from Leipzig University, where he studied protease catalyzed peptide synthesis. After postdoctoral studies at the Institute for Protein Research in Pushchino (Russia), he moved
to the University of Göttingen where he developed a novel method for the production of peptides from recombinant peptide-multimers. After a postdoctoral fellowship with Bill Rutter at the University of California, San Francisco,
Dr. Schellenberger joined Genencor in 1994. Dr. Schellenberger is the author of over 40 scientific papers and an inventor on more than 70 issued and pending patent applications. He is also the recipient of the Karl Lohman award
of the German Society of Biochemists.
|Stefan Scherer, PhD ||Cellectis|
Senior Vice President, Clinical Development and Deputy CMO
is a board-certified physician, bringing more than two decades of medical and scientific research and business experience from his time at various pharma and biotech companies to Cellectis. In his prior role as Head of Early Development,
Strategy and Innovation for U.S. Oncology at Novartis, Stefan was responsible for the strategic direction and management of the Company’s immuno-oncology and targeted therapy portfolios. In addition, Stefan built a comprehensive
clinical research alliance network and developed an immuno-oncology translational research team to harness scientific discovery for targeted patient outcomes.
|Taylor Schreiber, PhD ||Shattuck Labs|
CSO, Research & Development,
Taylor co-founded Shattuck Labs and
currently serves as Chief Scientific Officer and is a member of the Board of Directors. Taylor is the lead inventor of Shattuck’s ARC technology platform. Prior to Shattuck, Taylor served as Chief Scientific Officer of Heat
Biologics, Inc. where he was a co-inventor of significant elements of Heat's ImPACT and ComPACT technology platforms. He was also the co-inventor of TNFRSF25 agonist technology developed by Pelican Therapeutics, where he served
as Chairman of the Scientific Advisory Board. Taylor has numerous publications in the field of tumor immunology and immunotherapy, spanning the subjects of cancer vaccines, therapeutic proteins and antibodies, adenosinergic and
IDO mediated immunosuppression and regulatory T cell biology. In 2008, Taylor received the best overall research award at the National Student Research Forum and in 2011 he was nomited as a Future Leader in Cancer Research by the
American Association for Cancer Research. He received his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from
|Jane Seagal, PhD||AbbVie|
Principal Research Scientist, Global Biologics
Jane Seagal is a Principal
Research Scientist in Biologics Generation Group at AbbVie Bioresearch Center in Worcester, MA. She joined Abbott/AbbVie in 2010 and has been leading and supporting biologic drug discovery projects in Immunology, Oncology and Neuroscience.
Currently, she is leading the In Vivo Antibody Discovery Group and chairs the Biologics Generation Request Team responsible for biologics discovery and screening funnel strategies. Jane’s scientific training is in Immunology
focused on B cell biology and antibody responses. She received her PhD in Technion-Israel Institute of Technology and completed her post-doctoral training at Harvard Medical School.
|Lu Shan, PhD||MedImmune|
Scientist, Antibody Discovery & Protein Engineering
Dr. Lu Shan is a Scientist
in the Antibody Discovery and Protein Engineering group at MedImmune, the biologics division of Astrazaneca, where she is working toward the discovery and development of antibody therapeutics for multiple disease areas, as well
as leveraging technology innovation in drug discovery. Prior to Medimmune, she worked for Lexicon Pharmaceuticals supporting novel assay development and screening for DNA-encoded small-molecule libraries. She received her PhD in
Chemical Engineering from Stanford University and a postdoctoral training from Baylor College of Medicine in the area of transcription factors.
|Dellatore Shara, PhD||Merck and Co|
Director, Regulated Immunogenicity and Molecular Biology Bioanalytics
has experience in complex product characterization of monoclonal antibodies and therapeutic protein products. Some responsibilities include glycan, capillary electrophoresis, HPLC/UPLC assay method development and testing support
for biologics products. She developed and implemented extended characterization strategy to support Phase I and Phase III IND submissions. Shara is also an author and reviewer of FDA regulatory submissions and associated supporting
technical reports and memos. She also has experience with quality by design (QbD) and leader of critical quality attribute (CQA) team. Shara got her PhD from Northwestern University.
|Susan Sharfstein, PhD||SUNY Polytechnic Institute|
Professor, Nanobioscience, Nanoscale Science and Engineering
is a Professor of Nanobioscience at SUNY Polytechnic Institute in Albany, New York. Professor Sharfstein received her B.S. in chemical engineering with honors from Caltech in 1987 and her Ph.D. in chemical engineering from UC Berkeley
in 1993, receiving graduate fellowships from the university and the National Science Foundation. She received a National Institutes of Health Individual Research Service Award to pursue postdoctoral studies, initially at UC Berkeley
and subsequently at the UCLA Medical School. Professor Sharfstein received an NSF CAREER grant in 2000 for her work on hyperosmotic stress responses of hybridoma cells and the School of Engineering Education Excellence Award and
the Class of 1951 Outstanding Teaching Award in 2007. Professor Sharfstein’s research interests include mammalian and microbial cell bioprocessing, control of protein glycosylation, metabolic engineering, biosensing, and
development of systems for high-throughput screening of nucleic acids and small molecules. Professor Sharfstein serves as the subject editor for biotechnology for the Elsevier Major Reference Work Life Science Module. She is the
author of over 60 papers and book chapters in the fields of biotechnology and bioprocessing. She was a 2017-18 recipient of a Fulbright Global Scholar award and spent her sabbatical at Dublin City University, in Dublin, Ireland
and University of Queensland in Brisbane, Australia performing proteomic analysis of Chinese hamster ovary cells and studying bispecific antibodies.
|Vaneet K. Sharma, PhD||International AIDS Vaccine Initiative (IAVI)|
Manager, Analytical Development, Vaccine Development & Manufacturing
Sharma is Manager, Analytical Development in the Vaccine Development & Manufacturing division of International AIDS Vaccine Initiative (IAVI). He is responsible for the analytical methods development and physiochemical characterization
of the recombinant protein-based HIV vaccine candidates for Phase I/II clinical trials. Prior to this position, Dr. Sharma was a scientist, technical development at Novartis Vaccines. Dr. Sharma is also member of the USP Viral
Vaccines Expert Panel (2015-2020). Vaneet received his PhD from Northeastern University, MS from University of Connecticut, and BS from G.N.D. University, India.
|Joseph Shiloach, PhD||NIDDK, NIH|
Director, Biotechnology Core Lab
Adjunct Professor, Johns Hopkins University,
Department of Chemical and Biochemical Engineering, 2004. Ph.D., Hebrew University, Israel, 1975. My laboratory’s main interest is the production and purification of biological products from both prokaryotes and eukaryotes
of native and recombinant strains. Our work involves all aspects of this process including research, development, and production.
|Anthony Shock, PhD||UCB|
Director, Immunology Research
Anthony Shock received his PhD in Biochemistry
from the University of London in 1987 followed by post-doctoral work at the National Heart & Lung Institute in London. He was then employed by a Biotech company called Celltech which eventually transformed into the global biopharmaceutical
company, UCB. He has researched on a wide range of antibody-based therapies, including two antibody targets that have been evaluated in patients with systemic lupus erythematosus, epratuzumab and dapirolizumab pegol, and rozanolixizumab
which is currently in phase 2 clinical studies in patients with immune thrombocytopenia and myasthenia gravis, which are autoimmune disorders driven by IgG autoantibodies.
|Arun K. Shukla, PhD||Wellcome Trust DBT India Alliance, Indian Institute of Technology, India|
Chair, Professor and EMBO Young Investigator Intermediate Fellow
did his Masters (M.Sc.) in Biotechnology from the Center for Biotechnology at Jawaharlal Nehru University, New Delhi. He then completed his Ph.D. from the Department of Molecular Membrane Biology at the Max Planck Institute of
Biophysics in Frankfurt, Germany under the supervision of Prof. Hartmut Michel (Nobel Laureate, 1988). Dr. Shukla did his post-doctoral work with Prof. Robert Lefkowitz (Nobel Laureate, 2012) in the Department of Medicine at Duke
University in North Carolina, USA in a very close collaboration with Prof. Brian Kobilka (Nobel Laureate, 2012) in the Department of Cellular and Molecular Physiology at Stanford University in San Francisco, USA. Dr. Shukla is
currently an Associate Professor in the Department of Biological Sciences and Bioengineering at IIT Kanpur. Dr. Shukla’s research program is focused on understanding structure, function and regulation of G Protein-Coupled
Receptors (GPCRs), the largest family of cell surface receptors in the human genome and the target of about half of the currently available medicines.
|Zhang Shuli, PhD||Merck and Co|
Principal Scientist, PPDM Global Bioanalytics
Shuli manages a group of scientist
to develop PK, immunogenicity and biomarker assays for biologics, set up strategy and manage bioanalytical outsourcing to CROs, publish and review technical reports and regulatory documents. Shuli got his PhD from Indiana University
School of Medicine in the Immunology and Microbiology.
|Sheila K. Singh, MD, PhD FRCS(C)||McMaster University|
Director or McMaster Surgeon Scientist Program & Professor of Surgery
Sheila Singh is a professor of surgery and biochemistry, chief pediatric neurosurgeon at McMaster Children’s Hospital, the Division Head of Neurosurgery at Hamilton Health Sciences, and scientist appointed to the Stem Cell
and Cancer Research Institute at McMaster University. She holds a Tier 1/Senior Canada Research Chair in Human Brain Cancer Stem Cell Biology and is Director of the McMaster Surgeon Scientist Program. Her PhD thesis described the
novel identification of a population of cancer stem cells that exclusively drive the formation of brain tumours. Since 2007, Dr. Singh's lab applies a developmental neurobiology framework to the study of brain tumorigenesis. Building
upon previous cell culture techniques developed for the isolation of normal neural stem cells (NSC) and applying them to brain tumours, and through development of a xenograft model to efficiently study brain tumour initiating cell
(BTIC) activity, Dr. Singh's lab aims to understand the molecular mechanisms that govern BTIC self-renewal. Dr. Singh is currently studying the regulation of BTIC signaling pathways in glioblastoma, brain metastases and childhood
medulloblastoma, with an ultimate goal of selectively targeting the BTIC with appropriately tailored drug and molecular therapies. Her laboratory is funded by CCSRI, CIHR, TFRI, CRS, the Stem Cell Network, McMaster Surgical Associates,
Brain Canada and the Boris Family Fund.
|Anupam Singhal||Berkeley Ligts, Inc.|
The Beacon™ Platform for the Rapid Discovery of Rare Antibodies to Difficult Targets
Anupam Singhal earned his PhD from the University of British Columbia and has over 15 years of experience in nanotechnology and microfluidics at UBC, the University of Toronto and Stanford University. His work has been cited
over 600 times and resulted in patents now licensed and commercialized for molecular disease diagnosis, the discovery of antibody therapeutics, and development of cell-lines for bioproduction. At Berkeley Lights, Anupam leads the
design and development of next-generation platforms for the discovery and development of biologics.
|Will Singleterry, PhD||IsoPlexis|
Director, Business Development
Will Singleterry, PhD, Director of Business
Development at IsoPlexis, who uses a single cell proteomics platform to accelerate development of therapies by revealing the highly functional cell subsets driving clinical response. Dr. Singleterry manages collaborations between
IsoPlexis and Bio-Pharmaceutical partners for clinical trial biomarkers, early stage discovery and biomanufacturing applications.
|Michael J. Smanski, PhD||University of Minnesota|
Assistant Professor, Biochemistry, Molecular Biology & Biophysics, Biotechnology Institute
Michael Smanski is an Assistant Professor at the University of Minnesota in the Department of Biochemistry, Molecular Biology, and Biophysics and the BioTechnology Institute. Dr. Smanski received a B.S. degree in Biochemistry
and Cell Biology from the University of California – San Diego and a Ph.D. in Microbiology from the University of Wisconsin, where he deciphered the genetic and biochemical basis for the production of antibiotics platensimycin
and platencin by Streptomyces platensis. As an HHMI Fellow of the Damon Runyon Cancer Research Foundation, he worked with Chris Voigt at MIT to develop a comprehensive pipeline for the design, construction, and analysis of large
libraries of multi-gene plasmids. He is a recent the recipient of the Dale F. Frey Award for Breakthrough Scientists. Dr. Smanski’s goal is to develop enabling technologies to engineer biology in ways that address challenges
in medicine, agriculture, and the environment.
Head of Biologics, US
Christopher Smith, Head of Biologics US, Genedata Christopher Smith
is Head of Biologics, US at Genedata Inc. Dr. Smith develops data management solutions for biopharma and biotech companies to support their biologics drug discovery and development programs. This includes bioprocess analysis and
consultation as well as end-to-end workflow support solutions for antibody and protein screening, engineering, expression, and purification. He earned his Ph.D. at the University of California, San Francisco in Biochemistry and
|Eric Smith, PhD||Regeneron Pharmaceuticals|
Dr. Eric Smith received his PhD in Microbiology and Immunology
from Duke University in 1997. Following a postdoctoral fellowship at NYU, he joined Regeneron in 2002 as a member of the Antibody and Trap Technologies group, where he worked on cytokine traps and related molecules. In 2008, he
became a member of the Bispecific Antibodies team and is currently the Director of Bispecifics at Regeneron.
Senior Manager, Statistics
Perceval Sondag holds a Bachelor Degree in
Physical Therapy and a Master’s Degree in Biostatistics, both obtained from the Catholic University of Louvain-la-Neuve in Belgium. After starting his career by implementing statistical thinking in the newly created Operational
Excellence department of the Brussels Saint-Luc University Hospital. He joined Arlenda in 2013 as a Statistician consultant, and moved to the US based team in 2015. He specializes in Bayesian modelling and statistics applied to
bioassays and process manufacturing. In addition to his job at Arlenda, providing statistical support for small and big pharmaceutical companies across the globe, he currently works on a PhD thesis about Similarity Testing for
Bioassays. He is a member of the USP Expert Panel for Bioassays and has authored or co-authored multiple publications, including a book chapter on assay validation.
|Paul M. Sondel, MD, PhD||UW Carbone Cancer Center and American Family Children’s Hospital, University of Wisconsin|
Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics, and Director of Research, UW Division of Pediatric Hematology, Oncology and BMT
Paul Sondel, MD, PhD is the Reed and Carolee Walker Professor of Pediatrics, Human Oncology and Genetics and Director of Research for the Division of Pediatric Hematology, Oncology and BMT at the University of Wisconsin, Madison
(UW). He has focused on basic, translational and clinical cancer immunotherapy since 1969. Following BS-1971 and PhD- 1975 (UW, mentored by BMT pioneer, Fritz Bach, MD), MD- 1977 (Harvard Medical School) and residencies at U. of
Minnesota and UW, he joined the UW faculty in 1980. He was Head of PHO-BMT from 1990 – 2016, and helped lead cancer immunology research at the UW-Carbone-Cancer-Center (UWCCC) since 1990. His laboratory has pursued strategies
for enabling immune responses to impact on cancer; some have moved into clinical testing in adults at the UWCCC and in children through the COG. This includes collaborative development of an FDA-approved immunotherapy regimen (dinutuximab+
IL2+ GM-CSF) for children with neuroblastoma. He has held multiple committee/leadership roles, including at the NIH/NCI, American Cancer Society, Children’s Oncology Group, and St. Jude’s Children’s Research Hospital.
He has been a scholar of the Leukemia Society of America, recently received a 7-year Outstanding Investigator Award from the NCI, and the SITC’s Smalley Award for 2017. He has published more than 390 scientific articles and
chapters, and trained more than 70 graduate students and post-doctoral fellows in his lab. He also enjoys biking and canoeing; but most of all, he and his wife of 45 years (Sherie) love being parents and grandparents.
|An Song, PhD||Immune-Onc Therapeutics, Inc.|
Senior Vice President, Development Sciences
An Song, Ph.D, is Senior Vice
President of Development Sciences at Immune-Onc Therapeutics, Inc., accountable for translational development of Immune-Onc’s portfolio, including preclinical PKPD and toxicology evaluation, clinical pharmacology, bioanalytical
and biomarker/diagnostic development and certain analytical aspects of technical development. Prior to Immune-Onc, An was a Senior Director in BioAnalytical Sciences at Genentech, where she led the Assay Development and Technology
group for the company’s large molecule portfolio globally. During her 16-year tenure at Genentech, An contributed to, and oversaw 40+ IND/CTA and BLA/MAA regulatory filings for products including Rituxan@, Avastin®, Herceptin®,
Lucentis ®, Kadcyla®, and Tecentriq®. Additionally, she played a significant role for the development and approval of Ocrevus®. An holds a B.S. in Biochemistry from Nanjing University in China. She received her
PhD. in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in immunology at Stanford University. Upon completion of postdoctoral work in T-cell activation she joined Stanford as
a Research Assistant Professor and as faculty of the Immunology Program. An has published a number of original manuscripts, review articles and book chapters, as well as contributed to several industry white papers on immunogenicity
and antibody Fc effector function evaluation. She is an active member of American Association of Pharmaceutical Scientist (AAPS), having served as an executive member of the Biotech Section and the chair of Therapeutic Product
Immunogenicity (TPI) Focus Group/Community.
|Tourdot Sophie, PhD||Pfizer|
Senior Principal Scientist
No bio available
|Gupta Soumi, PhD||Biomarin|
Director, Immunogenicity Assessment, BioMarin Pharmaceutical Inc.
received her Ph.D. in Microbiology from University of California, Davis in 2003, where the focus of her research was aimed at furthering our understanding of the immune correlates of protection towards a successful AIDS vaccine.
She pursued post-doctoral training in Immunology at Chiron Corporation where she investigated anti-HIV T and B cell-mediated responses in mucosal and systemic compartments following mucosal immunization with alphavirus-based replicon
particles encoding for HIV-Gag, Pol and Env. Following her post-doctoral training, she worked at Monogram Biosciences as a scientist in research and development, developing assays to characterize genotypic and phenotypic resistance
to HIV antivirals. While at Monogram, she also worked in oncology clinical data development. After five years at Monogram, Soumi joined Janssen Pharmaceuticals working in medical affairs in Infectious Diseases. Soumi joined BioMarin
in February of 2015 as a Director in Immunogenicity Assessment where she provides immunologic expertise to drug programs across developmental stages and develops immunogenicity and safety strategies for novel biologic therapeutics.
Soumi has over 15 years of experience in immunology and infectious disease, vaccinology, HIV drug resistance, oncology diagnostics and drug development.
|Christoph Spiess, PhD||Genentech|
Senior Scientist, Antibody Engineering
Christoph Spiess received his
PhD from the University of Konstanz (Germany). After completing his postdoctoral studies in the field of protein folding at Stanford University, he joined Genentech in 2007 and is currently a senior scientist in the Department
of Antibody Engineering. His group is involved in the development of technologies to identify and produce bispecific antibodies for research and clinical development, developability assessment of antibodies, and engineering of
antibodies for tissue specific targeting.
|Philipp Spycher, PhD||Paul Scherrer Institute |
PSI Founder Fellow, Center for Radiopharmaceutical Studies (CRS)
is a PSI Founder Fellow at the Paul Scherrer Institute (PSI) Villigen (Switzerland) since end of 2017 working on the site-specific modification of native antibodies. He studied at the University of Basel (Switzerland) Nanoscience
and at ETH Zurich (Switzerland) Biomedical Engineering with a focus on drug delivery and targeting. During his doctoral studies at ETH Zurich, he worked on protein and materials engineering for the site-specific immobilization
of proteins onto micro-patterned surfaces using enzymes. He then performed a post-doc at PSI Villigen on the site-specific modification of antibodies and fragments using enzymes for diagnostic and therapeutic applications. Dr.
Spycher has over 8 years experience with ADCs and materials engineering, he is particularly interested in the development of drug delivery systems for improved targeting.
|Kuldip Sra, PhD||CRISPR Therapeutics|
Dr. Kuldip Sra has over 25 years been work experience in biotech
and pharmaceutical industries. Currently, Dr. Sra is working as Senior Director, Late Stage Development at CRISPR Therapeutics. Previously. Dr. Kuldip Sra has worked at MedImmune/AstraZeneca Company for 17 yrs. Dr. Sra led Vaccine
Analytical Development and Characterization group at MedImmune at Mountain View site. Before joining MedImmune, Dr. Sra worked at Chiron Corporation, Emeryville, CA on Hepatitis C and HIV Viruses. At Sangstat Medical Dr. Sra worked
on developing immunosuppressive drugs for their use in organ transplants. Dr. Sra got his Ph.D. in Biochemistry at Seton Hall University, in New Jersey.
|Bradley St. Croix, PhD||National Cancer Institute, NIH|
Head, Tumor Angiogenesis Unit, Mouse Cancer Genetics Program
St. Croix received his Ph.D. in Medical Biophysics from the University of Toronto in 1998, under Dr. Robert S. Kerbel. He trained as a postdoctoral fellow in the laboratory of Dr. Bert Vogelstein at Johns Hopkins University under
a fellowship from the National Cancer Institute of Canada. In 2000, while at Johns Hopkins, Dr. St. Croix published in Science the first systematic gene expression profiling of human tumor endothelium. In 2002, he established the
Tumor Angiogenesis Group at the Center for Cancer Research, NCI. In 2007, his lab described the first systematic comparison of genes that can separate physiological and pathological angiogenesis. His laboratory now focuses on understanding
the role of cell surface receptors upregulated on tumor vasculature and utilizes mouse models to translate new molecular information on angiogenesis into the development of novel antibody-based treatments for cancer. For example,
by engineering conditional knockout mice his lab demonstrated that GPR124 is critical for angiogenesis of the developing CNS and TEM8 promotes tumor angiogenesis. Dr. St. Croix’s group has also demonstrated the therapeutic
potential of targeting tumor-associated vasculature through the development of antibody-drug conjugates (ADCs) targeting B7-H3/CD276 and TEM8. The ability of these new ADCs to selectively target pathological angiogenesis is extremely
important as current anti-angiogenic drugs, such as Avastin, cannot discriminate between normal angiogenesis (e.g., during ovulation, menstruation and wound healing) and that associated with disease.
Lasse graduated with a BSc. In Biochemistry from University College
London in 2008. He subsequently studied protein crystallography in the field of protein kinase signalling at the MRC National Institute for Medical Research in London, being awared a PhD. In 2013. A PostDoc followed at Imperial
College London, on structural and mechanistic studies of protein homeostasis. In 2017, Lasse joined GSK on the Future Leader Programme. Upon joining, he worked as a Senior Scientist in the biopharm high-throughput characterisation
group, screening molecules using a range of biophysical techniques and developing novel assay formats for challenging targets. Currently, Lasse works in the biopharm developability profiling group as scientific investigator, where
his responsibilities include the biophysical developability assessment of biopharm lead molecules.
|Martin Steegmaier, PhD||Roche Innovation Center Munich|
Head of Discovery, Large Molecule Research, Roche Pharma Research and Early Development (pRED)
Martin earned his PhD in biochemistry from the University of Basel, Switzerland studying molecular mechanism of inflammation at the Max-Planck- Institute for Immunology in Freiburg, Germany. Before joining the pharmaceutical
industry, he spent 4 years as a postdoctoral fellow in the laboratory of Prof. Richard Scheller at Stanford University Medical School elucidating the biochemical mechanisms underlying neurotransmitter secretion. In 2000, he joined
Boehringer Ingelheim’s Oncology Drug Discovery Department and held positions with increasing responsibility. Martin joined Roche in 2006 in Basel and has held a number of positions since then. In his current role as Head
of Discovery in Large Molecule Research, Martin is responsible for a team of approximately 90 scientists and research associates who generate and profile new therapeutic antibodies for the different therapeutic areas within Roche
Pharma Research and Early Development (pRED). Furthermore, the discovery unit is responsible for designing and discovering novel biotherapeutic formats including pREDs proprietary bispecific antibody format CrossMab and the brain
shuttle technology to combat brain disorders.
|Dearmey Stephanie, MD||Duke University Medical Ctr|
Pediatrician, Pediatrics, Medical Genetics
No bio available
|Keri A. Streby, MD||Nationwide Children's Hospital|
Pediatric Oncologist, Hematology & Oncology
Dr. Streby is a pediatric
oncologist in the Division of Hematology/Oncology/BMT at Nationwide Children's Hospital and an assistant professor at The Ohio State University. Dr. Streby received her undergraduate degree from the University of Akron and completed
her medical degree from Northeastern Ohio Universities College of Medicine. She went on to complete her pediatric residency and pediatric hematology/oncology fellowship at Nationwide Children's Hospital. Dr. Strebys research and
clinical interests are focused on embryonal solid tumors, especially neuroblastoma. Her current research utilizes an oncolytic herpes virus and gene therapy to enhance targeted radiotherapy with 131I-mIBG for children with neuroblastoma.
|Robert M. Stroud, PhD||University of California, San Francisco (UCSF)|
Professor, Biochemistry and Biophysics, Pharmaceutical Chemistry, Macromolecular Structure Group (MSG)
A world leader in structural biology, Dr. Stroud's research has addressed a breadth of systems that impact a wide array of biological processes. This work has aimed to understand the molecular level cellular signaling and communication
across cell membranes, and the macromolecular encoding of specificity and affinity at protein/protein and protein/ligand interfaces. Dr. Stroud has more than 340 peer reviewed publications and 300 structures to his credit. Dr.
Stroud's contributions have been recognized by his election to the Royal Society of Medicine, the National Academy of Sciences, and the American Academy of Arts & Sciences. Dr. Stroud is Professor of Biochemistry and Biophysics
and Professor of pharmaceutical Chemistry in the Department of Department of Biochemistry and Biophysics. He received his PhD from University of London and completed postdoctoral training at California Institute of Technology.
Dr. Stroud joined UCSF in 1976 to start the University's first structural biology program.
|Christopher Sucato||Charles River|
No bio available
|Chaitanya Sudrik, PhD||Massachusetts Institute of Technology|
Postdoctoral Associate, Molecular Engineering
Dr. Chaitanya Sudrik is
a postdoctoral associate in Prof. Bernhardt Trout’s lab at the Massachusetts Institute of Technology. In his postdoctoral research, Dr. Sudrik has worked on several projects involving the characterization of protein-excipient
interactions and their effect on the aggregation and viscosity behavior of high concentration monoclonal antibody formulations with an eye towards the rational design of such formulations. Prior to joining MIT, Dr. Sudrik received
his PhD in chemical engineering from Rensselaer Polytechnic Institute, under the guidance of Prof. Ravi Kane. His thesis research focused on the development of novel molecular switches for the construction of synthetic biological
circuits inside mammalian cells.
|Traian Sulea, PhD||National Research Council Canada|
Senior Research Officer, Human Health Therapeutics
Dr. Traian Sulea
has joined NRC Canada at its Biotechnology Research Institute in Montreal as a post-doctoral fellow in 1995, and as a Research Officer in 1997. He is also cross-appointed as Adjunct Professor with the Institute of Parasitology
of McGill University since 2012. Dr. Sulea has broad expertise in applying computational approaches to the discovery and optimization of bioactive small-molecules and biologics. He has contributed to the development of computational
methods for biomolecular applications, focusing on continuum solvation models and binding-affinity scoring functions. In recent years, he applied computational structural modeling to the design of biotherapeutics including growth-factor
traps and avidity-optimized Intellimabs for tumor targeting, as well as to antibody humanization, affinity maturation and de novo design. Dr. Sulea has authored over 80 scientific articles and book chapters, and is an inventor
on 10 issued and 8 pending patents.
|Sabine Suppmann, PhD||Max Planck Institute for Biochemistry|
Head, Recombinant Protein Production
PhD in Microbiology at the University
of Munich “Design of New Selenoproteins”, PostDoc Student and Senior Scientist at Helmholtz Center Munich and Hoffmann-La Roche, Basel, Switzerland (Neurodegeneration, Immunology); since 2005 Head of Recombinant Protein
Production at the Max-Planck Institute of Biochemistry, Martinsried, Germany.
|Richards Susan, PhD||Sanofi|
Presidential Scientific Fellow, Translational Medicine Early Development,
Dr. Richards currently is a member of Translational Medicine Early Development (TMED) in Sanofi R&D where she contributes as global scientific expert in immunogenicity and chairs the TMED Immunogenicity Council. Previously,
she was the Head of the Clinical Laboratory Sciences Department in Sanofi/Genzyme Biologics R&D, responsible for four functional areas: Clinical Assay Development, Clinical Specialty Lab, CLS Quality Systems, and Investigative
Clinical Immunology. Assays were developed as “fit for purpose” including fully validated using various technology platforms (ligand binding, cell-based, flow-cytometry, molecular, LC-MS/MS) for bioanalysis of PK, biomarkers
and immunogenicity of biotherapeutics in clinical development. Clinical Specialty Lab is CLIA certified in Immunology, Clinical Chemistry and Urinalysis and supports clinical trials and post-marketing requirements. Research activities
included investigating the use of methotrexate for immune tolerance induction. Dr. Richards has also been an active member of the American Association of Pharmaceutical Scientists (AAPS) for over 15 years and currently is the Past
Chair and a Steering Committee member of the Therapeutic Product Immunogenicity Focus Group (TPIFG).
|Philip Tagari, PhD||Amgen|
Vice President, Research
Philip Tagari is currently Vice President of Research
(Therapeutic Discovery) at Amgen Inc, the world’s largest biotechnology company. His laboratories are responsible for biologics discovery, scaffold engineering, optimization and early manufacturability assessment; medicinal,
oligonucleotide and peptide chemistry; protein conjugates (ADC, peptibodies) and reagents; assay development, screening, enzymological and pharmacological characterization and profiling (in vitro), as well as structural biology,
biophysics, computation and modeling, analytical chemistry, materials logistics and automation. Prior to joining Amgen in 1998, Philip was a Research Fellow at Merck Frosst (Canada) Inc, where he contributed to several programs
in eicosanoid and inflammatory biology, culminating in the discovery of odanacatib and rofecoxib, as well as the clinically active leukotriene D4 receptor antagonist MK-571 and the leukotriene biosynthesis inhibitor MK-591. In
addition to the elucidation of leukotriene metabolism in several species, Philip established one of the first robotic screening laboratories at Merck, building on work performed at McGill and Oxford Universities on automated image
analysis, quantitative immunohistochemistry and neurotransmitter measurements in neurodegeneration and cerebrovascular research. Philip is a graduate of Gonville & Caius College, Cambridge University (UK).
|Yuichiro Takagi, PhD||Indiana University School of Medicine|
Associate Professor, Department of Biochemistry and Molecular Biology
Takagi is an Associate Professor in Indiana University School of Medicine. He received a BS degree from Ibaraki University, a MS degree from The University of Tokyo, and PhD degree in biochemistry from University of Oklahoma. He
conducted a postdoctoral research at the laboratory of Dr. Roger Kornberg (Nobel Laureate 2006) at Stanford University. Takagi laboratory is interested in understanding the mechanisms of assembly, structure and function of large
multi-protein complexes -“molecular machines” - involved in eukaryotic gene regulation. His lab is particularly interested in development of new expression technologies, which enable productions of large and often problematic
proteins and protein complexes for structural (x-ray crystallography, and cryo-EM), and functional studies.
|Hiroyuki Takeda, PhD ||Ehime University|
Associate Professor and Principal Investigator, Division of Protea-Drug-Discovery Sciences, Proteo-Science Center
Hiroyuki Takeda, Associate Professor, Division of Proteo-Drug-Discovery Sciences, Proteo-Science Center, Ehime University. He received his Ph.D. degree at Hiroshima University, Japan in 2004. Soon after that he joined NEDO national
project, as a postdoctral fellow, and tackled development of protein library and high-throughput screening of human protein kinases. In 2006, he moved to Oxygenix Co., Ltd., a start-up biotechnology company, and worked in Singapore
in protein drug-delivery system team. After he came back to Japan, he participated in a bio-ethanol project in Kyoto University as a postdoctoral fellow from 2008 to 2010. In 2011, he began to work at Ehime University as an Assistant
Professor. There he joined Professor Yaeta Endo and Tatsuya Sawasaki’s laboratory, which is famous for the development of wheat cell-free protein production. He became an Associate Professor and a principal investigator as
well in 2016. His interest consistently focuses on development of methodology for drug discovery, such as membrane protein production, antibody production, protein array, and high throughput screening.
|Rastislav Tamaskovic, PhD||University of Zurich|
Head, TC Facility, Biochemistry
Dr. Rastislav Tamaskovic is head
of TC facility at the Department of Biochemistry, University of Zurich. After completing PhD at the Paul Scherrer Institut (PSI), Switzerland, he joined as a postdoctoral fellow the Friedrich Miescher Institute (FMI) in Basel.
Here he pioneered the work on tumor suppressor protein kinase NDR and postulated its function in cell cycle progression and mitotic exit network. He and his colleagues also unveiled ‒ based on studies with knockout animals ‒ the
crucial role of PKB kinase in the maintenance of cell survival via counteracting p53-dependent apoptosis. In 2005, he joined Plückthun’s laboratory at the University of Zurich where he initiated and led the SCL project
on next generation of tumor targeting of ErbB family receptors. Among other anti-tumor compounds, he and his coworkers invented the bispecific and biparatopic designed ankyrin repeat proteins (DARPins), a novel class of tumoricidal
agents triggering a potent apoptotic response in ErbB2-overexpressing breast tumors.
|Edit Tarcsa, PhD||Abbvie Bioresearch Center|
Director, Resesarch Fellow, DMPK-BA
Currently responsible for developing global
DMPK strategy for ADCs and Biologic therapeutics. Previously oversaw non-regulated bioanalytical support for biologics including developing novel methodologies (LBA, LC/MS, hybrid) to characterize biologics PK, immunogenicity and
ADC clearance mechanisms. Prior to Abbvie, completed a Postdoctoral fellowships in cell biology at Harvard Medical School, and at NIH, and received a PhD in biochemistry from the University Medical School of Debrecen, Hungary.
|Magdalena Tary-Lehmann, MD, PhD||Case Western Reserve University (CWRU) |
CSO, Cellular Technology Limited (CTL) & Adjunct Associate Professor of Pathology
Dr. Magdalena Tary-Lehmann is Co-Founding Scientist and Chief Scientific Officer for Cellular Technology Limited (CTL). Dr. Tary-Lehmann received her M.D. and Ph.D., both from the University of Tübingen, Germany. Her postdoctoral
training in Immunology was at the University of California, Los Angeles. She moved thereafter to Case Western Reserve University, where she was awarded tenure and appointed as Associate Professor in the Department of Pathology.
As Chief Scientific Officer for CTL she oversees the performance of immunology assays in CTL’s GCP, GLP- and CLIA compliant contract laboratory for various pharmaceutical and biotechnology clients.
|Ali Tavassoli, PhD||University of Southampton|
Professor, Chemical Biology
Ali Tavassoli is professor of chemical biology
at the University of Southampton. Ali currently leads an interdisciplinary team of scientists whose efforts are focused on the discovery and development of protein-protein interaction inhibitors. They have developed several new
platform technologies to enable the generation and screening of cyclic peptide libraries of over a hundred million members. This work has resulted in the discovery of a series of first in class inhibitors of a variety of protein-protein
interactions. These compounds have served as chemical tools to allow deciphering and better understanding of cellular pathways. They also form the starting point for the development of therapeutic agents that target key protein-protein
interactions in disease. These molecules are currently progressing towards the clinic in collaboration with several pharmaceutical companies. Ali was Chair of the RSC's Chemical Biology and Bioorganic Group (2012-2015), and an
elected member of the RSC's Chemistry and Biology Interface Division council (2012-2016). Ali has won a number of awards during his career, including the European Association for Chemical and Molecular Sciences' medal for European
Young Chemist (in 2008) and the Royal Society of Chemistry’s Medimmune Protein and Peptide Award (2017).
|Ronen Tchelet||Dyadic International Inc.,|
Ronen Tchelet joined Dyadic in May 2013 and has been Dyadic’s
Vice President of Research and Business Development since January 2016. Dr. Tchelet received his Ph.D. in Molecular Microbiology and Biotechnology from Tel Aviv University in 1993 and did his postdoctoral as an EERO fellow at the
Institute of Environmental Science and Technology (EAWAG) in Switzerland. In the late 2000’s, he joined the API Division of TEVA Pharmaceutical Industries LTD., where he served as a Chief Technology Officer of Biotechnology.
Dr. Tchelet leaded and directed the Research and Development Biotechnology department of TEVA’s fermentation plant in Hungary. In his work he managed and organized Biotechnology and Biosimilar projects that combined multidisciplinary
areas such as development, operation, and production of API and biologics. In addition, from 2000 – 2005, Dr. Tchelet was the QA manager of COPAXONE® the flag ship TEVA¹s innovative drug. From 2007 through 2013,
prior to joining Dyadic, Dr. Tchelet became the founder and the Managing Director of Codexis Laboratories Hungary kft. (CLH) and a Vice President of Codexis Inc. At CLH, he established a state-of-the-art laboratory for strain engineering
and all aspects of fermentation work including process optimization and scaling up. It was during this time that Dr. Tchelet engaged with the C1 technology that was successfully developed for the Biofuel and the Bio-Industrial
|Christopher Thanos, PhD ||Actym Therapeutics |
Dr. Christopher Thanos is currently the CEO and Cofounder of Actym Therapeutics, Inc.
Previously he was head of Biotherapeutics Discovery at Halozyme Therapeutics (Nasdaq:HALO), where led efforts in Protein Engineering, Protein Production, Cell Biology and Immunology. Before that, he held roles at Sutro Biopharma,
Catalyst Biosciences (Nasdaq:CBIO), and Sunesis Pharma (Nasdaq:SNSS). Dr. Thanos has a Ph.D in Molecular Biology and Biochemistry from UCLA where he was a NIH Chemistry/Biology Interface Predoctoral Fellow. Following that, Dr.
Thanos was National Cancer Institute Postdoctoral Fellow at UCSF and Sunesis.
|Rispen Theo, PhD||Sanquin|
Principle Investigator, Antibody Structure and Function
Theo Rispens studied
chemistry in Groningen, The Netherlands. He received his PhD in 2004 following research of chemical reactivity in biological models systems. Since 2006 he has worked at Sanquin, where is staff member at the department of Immunopathology
of Sanquin Research. Current research activities focus on the structure and function of immunoglobulins and the mutual interactions between the immune system and therapeutic antibodies. One research line involves mechanisms of
humoral tolerance, in particular the biology of IgG4 antibody responses in health and disease. Furthermore, he studies the immune response to biologicals in autoimmune patients, particularly in rheumatology, and is responsible
for the development of novel immunoassays to support this research line, and to implement for world-wide service testing at Sanquin Diagnostic Services, to support the optimization of treatment strategies with biologicals.
|Goletz Theresa, PhD||EMD serono|
Global Head, NBE Drug Disposition
Theresa (Terry) Goletz is currently the
Global Head of New Biological Entities Drug Disposition for EMD Serono where she oversees the bioanalytical support for all large molecule programs from discovery through registration. Prior to her current position, Terry served
as a Director of Medical Sciences, Clinical Immunology at Amgen Inc. (Seattle WA) where she was the site head for Clinical Immunology. Her responsibilities included preclinical and clinical immunogenicity assessment, biological
sample management, and cytometry services as well as immunogenicity assay development and validation compliant with GLP/GCP/CLIA. Prior to Amgen, Terry held positions of increasing responsibility at Centocor Inc., a Johnson &
Johnson company initially leading a team focused on the discovery and validation of new adjuvants and vaccine targets, an extension of her academic laboratory’s focus and NIH training. After several years, she was asked to
form a new group dedicated to immunogenicity prediction and immune monitoring. In addition to these responsibilities, Terry managed external collaborations and served as an SME for vaccines, gene/immunotherapies, drug delivery
and immunogenicity. She has consulted on biotherapeutic drug development, authored over 30 publications and holds multiple patents.
|Holger Thie, PhD||Boehringer Ingelheim Pharma GmbH & Co. KG|
Senior Manager, Technology and Innovation, Biologics Development
Senior Manager Technology and Innovation at Boehringer Ingelheim. 2015-2018: Lab Head Molecular Biology at Boehringer Ingelheim. 2010-2015: R&D Project Manager at Miltenyi Biotec. 2005-2010: PhD student + PostDoc at Stefan
Duebels Lab at the Braunschweig University. 1999-2004: Studies of Molecular Biotechnology at the Bielefeld University
|Greg M. Thurber, PhD||University of Michigan|
Asst Professor, Chemical Engineering and Biomedical Engineering
Greg M. Thurber
is an Assistant Professor of Chemical Engineering and Biomedical Engineering at the University of Michigan. His work focuses on applying fundamental biotransport principles to design novel therapeutics and molecular imaging agents.
Prof. Thurber received his training in protein therapeutics at MIT under the guidance of Dr. Dane Wittrup. He then completed his in vivo training in molecular imaging in the laboratory of Dr. Ralph Weissleder at Mass General Hospital
and Harvard Medical School. Since joining the faculty at Michigan, he has delivered 26 invited talks at major pharmaceutical companies, national and international conferences, and university departmental seminars. Prof. Thurber
works with several pharmaceutical companies as a consultant, collaborator, and/or member of their scientific advisory board. He and his students have presented their interdisciplinary work at chemistry, chemical engineering, and
pharmaceutical science conferences. Prof. Thurber has authored 39 peer-reviewed journal publications, 3 book chapters, and numerous conference proceedings. He has received several awards including an NIH K01 award and the National
Science Foundation CAREER award.
|Hickling Tim, PhD||Pfizer|
Immunogenicity Sciences Lead, Biomedicine Design
Dr Tim Hickling is Discipline
Lead for Immunogenicity Sciences at Pfizer. He obtained his Biochemistry degree and Immunology Ph.D. from the University of Oxford. He carried out post-doctoral training at Glaxo and the MRC’s National Institute for Medical
Research before taking up a lectureship at the University of Nottingham. Tim has worked on various aspects of innate and adaptive immunology in infectious and inflammatory diseases. Tim joined Pfizer in 2007 and has worked on early
stage vaccines and from early discover to late stage development of biotherapeutics. He is passionate about applying our growing knowledge of the immune system to the development of safe and effect therapies.
|John Timmer, PhD||Inhibrx|
Vice President, Research
John Timmer is the VP of Research at Inhibrx, and
leads single domain antibody discovery, protein engineering, and therapeutic strategy at Inhibrx. He has enabled many of Inhibrx’s therapeutic platforms, including the multivalent immune agonists, the multispecific checkpoint
inversion, and tuned cytokines.
|Vivian Trang, PhD||Seattle Genetics|
Scientist, Protein Sciences
Vivian Trang received her undergraduate degree
from U.C. Berkeley where she worked with Matt Francis to make protein-polymer conjugates. From there, she moved to U.W. Madison for her doctorate under Eric Strieter where she synthesized ubiquitin chains to study the intricacies
of ubiquitin signaling. After completing her thesis, Vivian began her postdoctoral work under Peter Senter at Seattle Genetics and was hired as a Scientist in the Protein Sciences department where she explores methods to improve
the tumor selectivity of antibody therapeutics.
|Mark Trautwein, PhD||Bayer AG|
Senior Scientist, Pharmaceuticals R&D, Preclinical Research, Expression Technologies
Trautwein obtained his doctorate in biochemistry from University of Tübingen, Germany. Mark joined Bayer in 2008 to establish transient & stable mammalian protein expression platforms for protein therapeutics. In his current
position, Mark leads the Expression Technologies group and is involved in antigen and antibody expression as well as cell line development. In his project leadership role, he has been advancing projects with different degrees of
maturity within oncology as well as ophthalmology, comprising mAbs, antibody drug conjugates, radioimmunoconjugates and various other formats.
|Shih-Chong Tsai, PhD||Development Center of Biotechnology, Taiwan|
Sr Research Scientist, Deputy Executive Director, Institute of Biologics
Shi-Chong Tsai has completed his PhD at the age of 36 from Indiana University and postdoctoral studies from Indiana University School of Medicine. He is the director of Devlepment Center for Biotechnology in Taiwan. He has published
more than 10 papers in reputed journals and 11 international patents.
|Andrew Tsourkas, PhD||University of Pennsylvania|
Andrew Tsourkas Ph.D. is Professor of Bioengineering
at the University of Pennsylvania. Dr. Tsourkas received his Bachelor’s degree in Mechanical Engineering in 1997 from Cornell University, his Master’s degree in 1999 from Johns Hopkins University, and his Ph.D. in Biomedical
Engineering from the Georgia Institute of Technology/Emory University joint Ph.D. program in 2002. He then conducted a post-doctoral fellowship in the Department of Radiology at Harvard University, before joining Penn in 2004.
Dr. Tsourkas is currently the co-Director for the Center for Targeted Therapeutics and Translational Nanomedicine and Co-Director for the Chemical and Nanoparticle Synthesis Core. He has over 100 peer-reviewed and invited publications
and was a recipient of the Wallace H. Coulter Foundation Early Career Award and the National Science Foundation CAREER Award. In 2015, Dr. Tsourkas was also elected as a fellow to the American Institute for Medical and Biological
Engineering. Dr. Tsourkas is an inventor on over a dozen patents and has founded four biotechnology companies. The broad goal of his research program is to develop targeted imaging and therapeutic agents, with particular expertise
in nanotechnology and bioconjugate chemistry.
|Mihriban Tuna,, PhD ||F Star|
Vice President, Drug Discovery
Mihriban has over 10 years’ experience
in antibody engineering and discovery and has successfully managed a number of collaborative drug discovery projects with big pharma. Prior to joining F-star, she worked in technology enhancement in Biopharm R&D at GlaxoSmithKline
(GSK) and in the selection and optimisation of lead domain antibodies (dAbs) at Domantis Ltd. Mihriban holds a PhD in Biochemistry from University of Sussex, UK, and a BSc in Biology from Middle East Technical University, Turkey.
|Thomas Tuxen Poulsen, PhD||Symphogen A/S|
Principal Scientist, Preclinical Development
Thomas Tuxen Poulsen
is principal scientist in biomarkers and companion diagnostics and is primarily responsible for translational biomarker strategies for Symphogen’s drug candidates in pre-clinical and clinical development. He has substantial
pre-clinical background of more than ten years within in vitro and in vivo pharmacology, with a specific focus on drug development of cancer therapeutic antibodies and antibody mixtures, and a strong academic background in molecular
cancer research, cancer biology and cancer gene therapy.
|Bob Vakamehr, PhD ||Fate|
Chief Development Officer,
Bahram (Bob) Valamehr is the Chief Development
Officer at Fate Therapeutics, overseeing the company’s early development activities including “off-the-shelf” cell therapy products derived from the company’s induced pluripotent stem cell platform. Previously,
Dr. Valamehr was the Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center
developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related
to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of
Chemistry and Biochemistry at UCLA.
|Daniel A. Vallera, PhD||University of Minnesota Masonic Cancer Center|
Lion Scholar and Professor, Director, Section on Molecular Cancer Therapeutics; Professor of Therapeutic Radiology
Dr. Vallera is Professor of Radiation Oncology at the University of Minnesota Masonic Cancer Center with a background in immunology and biological drug engineering. His 40-year career has focused on selective drug targeting with
over 200 peer-reviewed publications. His group has brought 4 targeted drugs to first-in-human trials. Studies now focus on a new genre of immunotherapy drugs called TriKEs (Tri-specific NK Engagers) that engage NK cells to kill
|Sander van Berkel, PhD||Synaffix B.V.|
Director, R&D Operations
Prior to Synaffix, Sander performed postdoctoral
research on novel conjugation methodologies for non-invasive cancer imaging at University of Oxford. Preceding Oxford, he worked at the Leibniz-Institute of Plant Biochemistry in Halle, Germany, as postdoctoral researcher focusing
on the synthesis of antitumor agent epothilone B and its derivatives. He holds a PhD and a MSc in Organic Chemistry from the Radboud University Nijmegen, the Netherlands. He is an inventor on multiple patents and has been author
of 40 peer-reviewed publications and reviews.
|Wilfred A. van der Donk, PhD||University of Illinois|
Richard E. Heckert Endowed Chair in Chemistry, Director of Graduate Studies, and Howard Hughes Medical Institute Investigator, Department of Chemistry
Wilfred van der Donk was born in the Netherlands and obtained his PhD at Rice University. After postdoctoral work at MIT with JoAnne Stubbe, he joined the faculty at the University of Illinois in 1997, where he currently holds
the Richard E. Heckert Chair in Chemistry. Since 2008, he is an Investigator of the Howard Hughes Medical Institute. Research in his laboratory focuses on combining organic chemistry and molecular biology to gain a better understanding
of the molecular mechanisms of enzyme catalysis and use that knowledge for bioengineering applications, of particular interest is the biosynthesis of antibiotics.
|Anne Verhagen, PhD||CSL Research, CSL Ltd.|
Director, Protein Biochemistry
Anne Verhagen completed her Ph.D at the University
of Melbourne, Australia. She then spent three years as a post-doctoral scientist at the German Cancer Research Centre, Heidelberg, Germany before returning to Australia where she took up a position at the Walter and Eliza Hall
Institute of Medical Research, Melbourne. Her research focused on identifying regulators of cell death pathways and culminated in multiple publications, including a first author publication in Cell in 2000 describing the discovery
of a protein called Diablo (also known as Smac). In 2002 she was appointed to the Institute’s faculty. In 2011, she joined CSL Research, based in Melbourne Australia, where she today is Director of Protein Biochemistry. A
major focus of her group in recent years has been the development of confocal microscopy based cellular assays to visualize the movement of proteins as they are internalized, recycled or degraded.
|Jawa Vibha, PhD||Merck|
Director and Lead, Predictive and Clinical Immunogenicity
Dr. Vibha Jawa
is currently a Director, Biologics and Vaccine Bioanalytics at Merck where she is responsible for developing a strategy and provides oversight and management of scientific programs for discovery, development and optimization of
biologics and vaccines. In this role, she is partnering with discovery and development groups to design better molecules. Dr Jawa received her bachelors in Biochemistry (1991) from Delhi University and her doctorate in Biochemistry/Immunology
(1998) from All India Institute of Medical Sciences, New Delhi, India with a thesis work studying the immune mechanisms behind autoimmune diseases followed by a postdoctoral fellowship at University of Pennsylvania on monitoring
the immune response to viral vectors. She continued to work in the field of gene therapy evaluating viral vectors for hemophilia therapy in the Bay area followed by City of Hope Cancer Centre Stem Cell and Gene Therapy group. At
Amgen from 2003-2016, her focus was to develop methods for assessing immunogenicity to biologics and the mechanisms behind development of immunogenicity. Her current research interests include evaluating immune response biomarkers
for early drug development and efficacy, immunogenicity prediction using in silico, in vitro and in vivo technologies, modeling impact of immunogenicity on PK and PD and their application to a system based approach, antigen processing
and presentation and the role of T cells in immune response to drug products. Vibha is a member of professional organizations like American Association of Pharmaceutical Scientists (AAPS) and American Association of Immunology
(AAI) and Federation of Clinical Immunology Society (FOCIS). Within AAPS, Vibha has been actively involved as a Steering Committee member of the Therapeutic Protein Immunogenicity Focus Group (TPIFG) and is currently leading the
Immunogenicity Prediction Action Program Area (IPAPA). She has been an invited speaker in multiple sessions at AAPS for past few years and has successfully moderated and organized programming at AAPS NBC (National Biotechnology
Conference) and AAPS Annual Meetings. She has also organized and participated in AAPS webinar and e forum to propagate learning and sharing information among AAPS members. Dr Jawa also serves as a manuscript reviewer for The AAPS
Journal and J. Pharm Sci Journal.
|Bjørn Voldborg, MSc||Technical University of Denmark|
Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability
Bjørn Voldborg has more than 20 years of experience working with recombinant protein expression from both academic and industrial settings. Bjørn was teamleader in the biotech company Pharmexa A/S, responsible for
molecular cloning and expression of proteinbased drug candidates. From this he went to the NNF Center for Protein Research at the University of Copenhagen as Head of the Protein Production Unit, and since 2012 Bjørn has
been heading the CHO Cell Line Engineering project at the NNF Center for Biosustainability at the Technical University of Denmark, a project dedicated to the engineering of improved protein production cell factories.
|Steven Walfish, MBA||USP|
Principal Scientific Liaison
Mr. Walfish brings over 30 years of industrial
expertise in the application of statistical methods for assay development and validation. Steven has experience applying statistical methods to all facets of the CMC process. Mr. Walfish is Principal Science & Standards Liaison
in the Global Science and Standards Division at United States Pharmacopeia (USP). Mr. Walfish holds a Bachelors of Arts in Statistics from the University of Buffalo, Masters of Science in Statistics from Rutgers University and
an Executive MBA from Boston University.
|Jihong Wang, PhD||AstraZeneca|
Dr. Jihong Wang is a principal scientist currently leading
late stage characterization group at MedImmune. She was the major contributor for IMFINZI® (durvalumab), FASENRA (benralizumab), and LUMOXITI (moxetumomab pasudotox) BLA filing. During her fourteen years at MedImmune, Dr. Wang
has been working on method development and qualification, peak identification for all lot release and characterization assays, product characterization including degradation pathway and CQA determination, for all types of molecules,
including mAbs, fusion proteins, bispecific molecules, ADC, etc. Her expertise is mainly on glycosylation characterization and mass spectrometry, more recently on multi-attribute-monitoring (MAM). Before joining MedImmune, Dr.
Wang worked on Protein Kinase substrates and Protease substrates in two biotech start-up companies in Boston area. She got her PhD degree in Chemistry from Rutgers University at New Brunswick working on Tat peptide-oligonucleotide
conjugates targeting HIV-1 TAR RNA.
|Lintao Wang, PhD||ImmunoGen, Inc. |
Associate Director, Analytical and Pharmaceutical Development
Dr. Lintao Wang
is currently the Associate Director in Analytical and Pharmaceutical Science (APS) at ImmunoGen. His areas of expertise include analytical and bioanalytical method development and mass spec (MS) analysis of proteins and small-molecule
compounds. Dr. Wang received his B.S. & M.S. degrees in Chemistry from Beijing University, and Ph.D. in chemistry from University of Nebraska-Lincoln (2002). He was trained as a protein biochemist and an analytical scientist
in Midwest Center for Mass Spectrometry (UNL). He joined ImmunoGen in 2002 and started his career in developing anticancer immunotherapies such as antibody-drug conjugates (ADC). In 2007 he joined Shire as a senior scientist for
tandem MS method development in Bioanalytical and Biomarker Development. In 2011, he rejoined ImmunoGen as the group leader for Mass Spec as well as the High Throughput Analytics. He supported ADC programs at all stages from antibody
cell line screening to late-stage in-depth structural characterization. Overall, with years of experience in protein analytics and a number of publications and conference presentations, Dr. Wang is a well-established analytical
chemist in the antibody and ADC development of the biopharma/biotech industry.
|Stacy Ward Ward, PhD||MilliporeSigma|
Senior R&D Scientist, Cell Design Studio, MilliporeSigma
Stacey received her Ph.D. in
Microbiology and Immunology from the State University of New York Upstate Medical University in Syracuse, NY, where she studied the dysregulation of cell cycle protein expression and activity by varicella zoster virus. She completed
a postdoctoral appointment at the University of Connecticut Health Science Center investigating herpes simplex virus DNA replication before being awarded an NIH-funded postdoctoral fellowship in brain cancer biology at Washington
University in St. Louis School of Medicine, dissecting the role of sonic hedgehog signaling in medulloblastoma. Stacey joined MilliporeSigma in 2016 and has been genetically engineering cells for customer and off-the-shelf products
as well as integrating the use of next generation sequencing in library deconvolution and expression.
|Gregory A. Weiss, PhD||University of California, Irvine|
Professor, Chemistry, Molecular Biology & Biochemistry
is a Professor of Chemical Biology at the University of California, Irvine (UCI). He earned a BS from UC Berkeley and a PhD from Harvard. His undergraduate and graduate research focused on the development of heterocyclic mimics
of peptides. Awarded a Ruth Kirschstein National Research Service Award from the NIH, he returned the funding to pursue post-doctoral studies with Dr. Jim Wells, then at Genentech. In 2000, he joined the faculty at UCI where his
laboratory focuses on the interface between chemistry and biology, including studies of enzymes, molecular recognition, and bioelectronics. His awards include Outstanding Professor in the School of Physical Sciences at UCI (elected
by the graduating students), Beckman Foundation Young Investigator, and election to Fellow of the American Association for the Advancement of Science. He has published around 100 peer-reviewed articles in chemical biology, biophysics,
biochemistry, molecular biology, and organic chemistry. He co-founded and was twice elected co-chair of the Global Young Academy, which includes 200 top young scientists from >55 countries. With Dr. David Van Vranken, he co-authored
Introduction to Bioorganic Chemistry and Chemical Biology. In 2015, he was awarded the Ig Nobel Prize in Chemistry for leading the team that partially unboiled the egg. He has started two biotech companies and is UCI’s Entrepreneurial
Leader of the Year in 2018. He and his wife live in Irvine, California with their three cats.
|Ron Weiss, PhD||Massachusetts Institute of Technology (MIT)|
Professor, Biological Engineering
Ron Weiss is Professor in the Department of
Biological Engineering and in the Department of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology, and is the Director of the Synthetic Biology Center at MIT. He received his PhD from MIT
in 2001 and held a faculty appointment at Princeton University between 2001 and 2009. His research focuses primarily on synthetic biology, where he programs cell behavior by constructing and modeling biochemical and cellular computing
systems. A major thrust of his work is the synthesis of gene networks that are engineered to perform in vivo analog and digital logic computation. He is also interested in programming cell aggregates to perform coordinated tasks
using cell-cell communication with chemical diffusion mechanisms such as quorum sensing. He has constructed and tested several novel in vivo biochemical logic circuits and intercellular communication systems. Weiss is engaged in
both hands-on experimental work and in implementing software infrastructures for simulation and design work.
|Duane R. Wesemann, MD, PhD||Brigham and Women’s Hospital|
Principal Investigator, Assistant Professor of Medicine, Harvard Medical School & Associate Physician
No bio available
|Tim Whitehead, PhD||University of Colorado, Boulder|
Associate Professor, Chemical and Biological Engineering
Tim Whitehead is
an Associate Professor at the University of Colorado, Boulder in the Dept. of Chemical and Biological Engineering. He has won an NSF CAREER award, holds 6 patents (5 licensed), and has published over 40 research articles in journals
like Science, Nature Biotechnology, and Nature Methods.
CEO and Co-Founder
Sajith is the CEO and Co-Founder of Benchling,
the leader in cloud informatics for life science R&D. He has led the company through remarkable growth, increasing adoption of its platform to over 160,000 scientists across top pharmaceutical companies and high-growth biotechs.
|Ian Wilkinson||Absolute Antibody, Ltd.|
Chief Scientific Officer
Ian’s background is firmly in the engineering
and development of therapeutic antibodies. Having solved the first NMR structure of a human antibody fragment (UCB-Celltech, University of Leicester) Ian oversaw therapeutic research projects covering technology validation, drug
discovery and optimization (MedImmune, AstraZeneca) before joining Absolute Antibody at its founding in 2012.
|Hallett William, PhD||FDA|
Biologist, OPQ/OBP, CDER
Will Hallett received his PhD in Cellular and
Molecular Biology from the University of Nevada, Reno in 2008. His postdoctoral studies on immunotherapy at the Medical College of Wisconsin and the University of Wisconsin-Madison led him to the FDA in 2012. He performs Product
Quality and Immunogenicity reviews for the Office of Biotechnology Products in CDER. He is a member of the OBP Immunogenicity Working Group.
|Erin Williams, MS||EMD Serono|
Associate Lab Head, Quality Control
Erin Williams started at EMD Serono as an Associate Scientist
I after completing her master’s degree in Molecular and Cellular Biology at the University of New Haven. Her role has changed significantly in the past five years, and she is now the Associate Lab Head of the Quality Control
team within the Protein and Cell Sciences department. When not at work, Erin enjoys spending quality time with her husband and two young sons.
|Pierre Wils, PhD||Sanofi|
Head, Biologics Formulation and Process Development
Recently appointed as
head of Formulation and Process Development Department of Sanofi Vitry site, Pierre was previously CMC Project Leader and PAI Task Force Leader for sarilumab (Kevzara®) leading the CMC team through successful submission and
registration of Kevzara in the US, EU and Japan. Prior to this, he held positions in pre-formulation and formulation development for small molecules, biotherapeutics and gene delivery technologies. Pierre graduated as an Engineer
from the Institut National Agronomique Paris, France, and received his PhD in Molecular and Cellular Pharmacology at the Institut Gustave Roussy in Villejuif, France.
|Patrick C. Wilson, PhD||University of Chicago|
Professor, Medicine & Rheumatology, Knapp Center for Lupus and Immunology Research, Committee on Immunology
Dr. Wilson is a Professor in the department of Medicine, section of Rheumatology at the University of Chicago. Dr. Wilson’s laboratory studies B cell biology with a particular emphasis on antibody specificity and B cell
selection. We characterize the human B cell response to infectious diseases such as influenza, and we study the fate, differentiation, and selection of B cells.
|K. Dane Wittrup, PhD||Massachusetts Institute of Technology|
C.P. Dubbs Professor, Chemical Engineering and Biological Engineering; Associate Director, Koch Institute for Integrative Cancer Research
Professor K. Dane Wittrup is the Carbon P. Dubbs Professor of Chemical Engineering and Biological Engineering at the Massachusetts Institute of Technology, and the Associate Director of the Koch Institute for Integrative Cancer
Research. From 1989 to 1999, he was Assistant Professor, Associate Professor, and then J. W. Westwater Professor of Chemical Engineering, Bioengineering, and Biophysics at the University of Illinois in Champaign/Urbana. Prof. Wittrup
received a BS in Chemical Engineering Summa cum Laude in 1984 from the University of New Mexico, and a PhD in Chemical Engineering from the California Institute of Technology in 1988 under the thesis direction of Prof. James Bailey.
Following a year of postdoctoral research at Amgen (Thousand Oaks, CA), Dr. Wittrup joined the faculty at the University of Illinois. Wittrup’s research program is focused on protein engineering of biopharmaceutical proteins
by directed evolution. Areas of interest include: pretargeted radioimmunotherapy, biological response modification of EGFR, and immunotherapy of cancer via engineered cytokines and vaccines.
|Liliana Wroblewska, PhD||Pfizer, Inc.|
Principal Scientist, Biomedicine Design
Liliana Wroblewska is a Principal
Scientist leading Molecular and Synthetic Biology group at Biomedicine Design Department, Pfizer, Inc. She completed PhD training at the Georgia Institute of Technology, Atlanta, where she studied the landscape of physics-based
force fields in the context of protein structure prediction. Then she moved to Ron Weiss's lab at MIT, Cambridge as a Postdoctoral Scholar to work in the field of mammalian synthetic biology. She worked on RNA-based regulation,
engineering in vivo biosensors for interrogation of cellular states, and using synthetic biology to study transcriptional and posttranscriptional regulation in mammalian cells with the focus on cross-talk, insulation and orthogonality
in complex cellular environments.
|Wen Jin Wu, MD, PhD||Food & Drug Administration|
Senior Investigator, OBP, CDER
Dr. Wen Jin Wu currently is a Senior Investigator
in Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA. He earned his M.D. from Wannan Medical College, China and finished his Ph.D. at Cornell University in 2002. He was recruited as a Principal Investigator
(PI) in the Division of Monoclonal Antibodies in 2004. In addition to his regulatory duty as a product quality reviewer with expertise in the area of therapeutic monoclonal antibodies, antibody-drug conjugates, and biosimilars,
Dr. Wu’s laboratory focuses on understanding the roles of ERBB family receptors in breast cancer progression and the mechanisms of trastuzumab and T-DM1 resistance, and trastuzumab and T-DM1-induced toxicity. He has published
many papers in highly reputed journals, including Journal of Biological Chemistry, Nature, Cell, Molecular Cancer Therapeutics, and Cancer Research, and has been invited to give talks in many national and international conferences.
|Mingjie Xie||Rapid Novor, Inc.|
Mingjie received his M.Sc. degree in Computer Science from Western
University in 2006 and received his M.B.A from Richard Ivey School of Business in 2016. He is currently the co-founder at Rapid Novor Inc. Prior to co-founding Rapid Novor, he was the Chief Operating Officer at a bioinformatics
US Function Head, CMC Statistical Sciences, Vaccines Technical Research & Development
Yamagata is the US Function Head in CMC Statistical Sciences, Vaccines Technical Research & Development for GSK in Rockville, MD. Prior to joining GSK, Ryan was a consultant working with small biotech and medical device companies,
and has also worked for MedImmune/Astra Zeneca, Shire, and Wyeth. He has over 15 years of experience supporting preclinical and clinical studies, translational science, and CMC activities (formulation, process and method design
space characterization and optimization, process and method validation and transfer, stability). Ryan has an MS in Statistics from Brigham Young University and a BS in Mathematics from BYU-Hawaii.
|Xiaodong Yan||Biortus Biosciences Co., Ltd.|
Dr. Yan obtained his PhD from Purdue University. He was a professor at
UCSD for 14 years before joining Biortus. He is also a joint professor at Xiamen University where he established a Cryo-EM platform. Dr. Yan dedicated his research interest in structural modeling with modern technologies such as
|Harry Yang, PhD||Medimmune, LLC|
Senior Director, Statistical Sciences
Harry Yang, Ph.D., is Senior Director
and Head of Statistical Sciences at MedImmune. He is also the Membe of USP Statistics Expert Committee. Harry has published 5 statistical books, 14 book chapters, and over 90 peer-reviewed papers over diverse statistical and scientific
subjects. He is a frequent invited speaker at national and international conferences and workshops. He was also invited to develop statistical courses and conduct the training at the FDA, Chinese FDA, and USP. He received his BS
and MS degrees in Applied Mathematics from Peking University and Ph.D. in Statistics from the University of Pittsburgh.
|Alison Young, PhD ||FUJIFILM Diosynth Biotechnologies|
Staff Scientist, Mammalian Cell Culture
Alison Young has a PhD from the University of Newcastle
upon Tyne and has gained more than ten years’ experience working within the biotechnology industry. She is a Staff Scientist within the Mammalian Cell Culture group at FUJIFILM Diosynth Biotechnologies. Here, her work to
establish a robust cell line development platform process contributed to the launch of the Apollo™ mammalian expression platform system.
|Travis Young, PhD ||CALIBR|
Vice President, Biologics
Dr. Young is the Vice President of Biologics at
Calibr, a division of Scripps Research. He received a BS in biochemistry from Boston College and a PhD in chemical biology from The Scripps Research Institute as an ARCS scholar. At Scripps, his work focused on the development
of unnatural amino acid incorporation methodologies to improve the properties of therapeutic proteins. This work was foundational for the development of programs in the Calibr pipeline today, including a bispecific antibody for
prostate cancer which will enter clinical trials next year. After receiving his PhD, he completed a postdoc at Harvard Medical School with an NIH fellowship, in the department of Biological Chemistry and Molecular Pharmacology
with Dr. Christopher T Walsh.
|Mimi Cho Yung, PhD||Lawrence Livermore National Laboratory (LLNL)|
Staff Scientist, Biosciences and Biotechnology Division, Physical and Life Sciences Directorate
Dr. Mimi Cho Yung received her Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology in 2012 and conducted her postdoctoral work at Lawrence Livermore National Laboratory (LLNL). She is currently a Staff
Scientist at LLNL in the Biosciences and Biotechnology Division. Her research interests include the development of novel peptide/protein expression strategies and synthetic biology therapeutic applications using bacterial nano-
|Alexandra (Sasha) Zaitsev||ImmunoGen|
Head, Bioassay Laboratory, Analytical Development Department
I received my MS from the Kyungpook National University in South Korea.
I work at BIOCAD as a head of cell-based test unit under the direction of Natalia Kozhemyakina.
Our team performs optimization, automation, qualification and validation of cell-based assays as well as analytical support before 3rd phase of clinical trials, then we are responcible to conduct analytical transfer to quality control team.
Development Associate, Analytical & Pharmaceutical Sciences
Zaitsev is a Development Associate at the Analytical and Pharmaceutical Sciences department at ImmunoGen, Inc. She received her MS degree in Chemistry from Tufts University in 2015 and has previously worked with proteins and peptides.
Her work at ImmunoGen has been focused on developing analytical methods for antibodies, antibody-drug conjugates, and small molecule payloads. She is also involved in characterization testing of antibodies and ADCs and in supporting
forced degradation and administration set IV compatibility studies.
|Baochun Zhang, PhD ||Dana Faber|
Assistant Professor of Medicine, Department of Medical Oncology,
Medicine in China, Dr. Zhang pursued Ph.D training at the Medical College of Ohio, where he studied T cell tolerance and B cell lymphomagenesis. He then had his postdoctoral training with Dr. Klaus Rajewsky and Dr. Frederick Alt
at the Immune Disease Institute and Children’s Hospital Boston, Harvard Medical School, where he focused on understanding the pathogenesis of diffuse large B cell lymphoma, and immune surveillance against Epstein-Barr virus
(EBV)-infected/transformed B cells. Dr. Zhang is now an Assistant Professor at Dana-Farber Cancer Institute, Harvard Medical School, where his research group continues to explore the molecular basis of B cell malignancies and unravel
the mechanisms of EBV-induced immune surveillance, and leverages the resulting knowledge to develop new immunotherapy approaches for treating B cell malignancies as well as other cancers.
|Zhe Zhang, PhD ||Novartis Institutes for BioMedical Research|
Zhe Zhang works in Novartis focusing on biologics developability
assessment since 2016. In Integrated Biologics Profiling (IBP) group, Zhe provides profiling analysis for protein drug candidates by mass spectrometry. Before joining Novartis, Zhe received his Ph.D. in Chemistry from University
of Massachusetts Amherst focusing on mass spectrometry application for protein aggregation characterization. Zhe also earned his B.S. in University of Science and Technology of China.
|Jane Zhao, PhD||Immunogen|
Graduated in 1999 with a Ph.D in Analytical Chemistry from
University of Minnesota under the guidance of Professor Peter Carr. Joined Pfizer as Analytical scientist/project lead supporting drug candidates from preclinical to Phase II from 1999 to 2006. Relocated from Groton CT to Boston
in December 2006 and led a chromatography/mass spectrometry group in Cabot Corporation for over nine years before joining Immunogen in March 2016.
|Li Zhou, PhD||AbbVie|
Senior Scientist, Global Biologics
Li Zhou obtained his PhD in chemistry, studying
small molecule inhibitors of protein-protein interactions. He then joined the fragment based drug discovery (FBDD) group at AbbVie, conducting biophysical screening for lead ID. Currently, he heads a biomolecular interaction group
at AbbVie global biologics department.
|Lisa Zhou, PhD||AbbVie |
Senior Scientist, Protein Analytics
Liqiang (Lisa) Zhou has worked in Protein
Analytics Department of Abbvie Bioresearch Center since 2002. She has worked on the analytical characterization of a range of molecules including mAb, Dual Variable Domain Ig (DVD-IgTM) and antibody drug conjugate (ADC). She has
been the analytical lead for multiple projects in early and late stage development. Lately she has focused on tasks related to CQA risk assessment, IND and BLA drafting. Lisa received her M.Sc. in Chemistry from University of Illinois
at Urbana-Champaign (2000) and Peking University (1997).
|Qing (Joanna) Zhou, PhD||FDA|
Product Quality Team Leader, Division of Biotechnology Review and Research I (DBRR I), OBP, CDER
Dr. Qing Zhou is a product quality team leader in the Division of Biotechnology Review and Research I (DBRR I) in the Office of Biotechnology Products (OBP), CDER/FDA. Dr. Zhou joined the FDA in 2010 as an Interagency Oncology
Taskforce (IOTF) fellow and became a full time CMC/product quality reviewer in the Division of Monoclonal Antibody (DMA) in 2012. Dr. Zhou has extensive research experience in the areas of tumor and transplantation immunology and
immunotherapy. Currently, she performs and supervises the review of regulatory submissions at the FDA for a wide range of novel and biosimilar biotechnology products.
|Eugene Zhukovsky, PhD||Biomunex Pharmaceuticals|
Dr. Zhukovsky has over two decades of professional experience in
the field of biotherapeutics research and development. He currently applies optimized monospecific and novel bispecific antibody platforms to the development of immunotherapeutics for cancer, with a particular focus on leveraging
the biology of immune checkpoint modulators. Currently, Dr. Zhukovsky is the CSO of Biomunex Pharmaceuticals, and he also consults with other biotechnology companies. Previously, he served as the CSO of Affimed Therapeutics; there
he was responsible for the advancement of candidate therapeutics from discovery to the clinic, and novel technology development. Prior to that he was a Senior Research Fellow in the Biotherapeutics Department at Boehringer Ingelheim
Pharmaceuticals, Inc. leading antibody discovery efforts in the therapeutic areas of inflammatory and cardiovascular diseases. Prior to that Dr. Zhukovsky was an Associate Director at Xencor, Inc. where he led translational research
efforts resulting in several therapeutic candidates targeting malignant B cells. One of these therapeutic antibodies is currently undergoing late-stage clinical trials. Dr. Zhukovsky began his professional career employing phage
display technology at Neurex Corporation. He then moved to Lynx Therapeutics (now Illumina, Inc.) to work on the development of genomics technologies before returning to protein/antibody engineering and biotherapeutics development
at Xencor, Inc. Dr. Zhukovsky performed a postdoctoral fellowship at Genentech, Inc. He received a PhD in biochemistry from Brandeis University and an MS degree in bioorganic chemistry at St. Petersburg's State University.
|Stefan Zielonka, PhD||Merck KGaA|
Group Leader & Principal Scientist, Protein Engineering & Antibody Technologies, Discovery Technologies, Global Research and Development
Stefan received his PhD in 2015 from the Technische Universität of Darmstadt, Germany, where he worked in the Group of Harald Kolmar in the field of protein engineering of non-canonical antibodies. At the moment, he works
as Associate Director at Merck KGaA (EMD Serono), Germany, in the Department Protein Engineering and Antibody Technologies (PEAT).
|Qin Zou, PhD||Pfizer Inc.|
Group Leader, Analytical Research and Development
Qin Zou is currently the group
leader and associate research fellow at Pfizer, responsible for product and process characterization using various biophysical and biochemical techniques. Before joining Pfizer, he was with Eli Lilly and Co. and worked on formulation
development, analytical research and biophysical analysis for biotherapeutics. Qin Zou has a PhD in physical biochemistry from University of Iowa College of Medicine, specifically on thermodynamics of protein stability, protein
unfolding and protein interaction. He was also a postdoctoral fellow at Indiana University School of Medicine studying enzymology and protein crystallography.